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Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory disease 
characterized by airflow limitation, an impairment of lung function. Emphysema is a major 
pathological change of COPD and characterized by the destruction of lung parenchyma. COPD 
is the third leading cause of death worldwide. The primary environmental risk factor for COPD is 
cigarette smoking, but individuals vary in their susceptibility to the effects of cigarette smoke and 
only a minority of smokers will ever develop COPD. This indicates other factors besides 
smoking are involved in the development and progression of COPD, and these may interact 
with smoking. This dissertation investigates the genetic determinants of emphysema 
progression quantified by computed tomography (CT) imaging and studies gene-by-smoking 
interaction on COPD risk 1) at the genome-wide scale and 2) using a polygenic risk score 
approach. This dissertation uses data from the COPDGene and ECLIPSE study, a longitudinal 
cohort of current and former smokers measuring chest CT scan, and the UK Biobank, a large-
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Chapter 1. Introduction and literature review  
 
Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory disease 
characterized by airflow limitation, an impairment of lung function. COPD patients present 
persistent respiratory symptoms such as dyspnea, chronic cough, and chronic sputum 
production. COPD is caused by a mixture of two subtypes, small airways disease and 
parenchymal destruction (emphysema) 1. Emphysema is a major pathological change of COPD. 
It is characterized by the abnormal and permanent enlargement of distal airspaces along with 
destruction of lung parenchyma. As COPD is a highly heterogeneous disease, COPD patients 




The burden of COPD has increased in the last two decades. The Global Burden of Disease 
Study reported a prevalence of 251 million cases of COPD globally in 2016 2. It is estimated that 
5% (estimated 3.17 million deaths) of all deaths was caused by COPD in 2015. In the United 
States (U.S.), COPD became the third leading cause of death in 2014 3. COPD affects 5-10% of 
the U.S. population with an estimated 24 million affected individuals 4.  
 
COPD results in substantial economic and social burden. COPD is the second leading cause of 
reduced Disability-Adjusted Life Year (DALY) in U.S. The estimated direct and indirect costs of 
COPD are $32 billion and $20.4 billion, respectively, in U.S. 5. With the aging population and 
cumulative exposures to COPD risk factors, the burden of COPD is projected to increase over 
the next 30 years globally. By 2030, there may be over 4.5 million deaths annually from COPD 




Measurement of COPD 
 
Spirometry measure of lung function 
Spirometry measures two primary lung functions to assess an airflow limitation; forced 
expiratory volume in the first second (FEV1) is the volume of air forcibly exhaled in the first 
second and forced vital capacity (FVC) is the volume of air that can be maximally forcibly 
exhaled. The presence of a post-bronchodilator FEV1/FVC ratio less than 0.70 confirms the 
presence of airflow obstruction, and thus defines clinical COPD. The predicted post-
bronchodilator FEV1 grades disease severity of COPD into mild, moderate, severe and very 
severe according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria 1.  
Spirometry is a noninvasive and readily available tool to diagnose and assess COPD in the 
clinical setting. However, spirometry alone cannot distinguish two key subtypes of COPD: 
emphysema and small airways disease. COPD patients diagnosed based on spirometry alone 
still have significant differences in their underlying lung abnormality. 
 
CT measures  
Computed Tomography (CT) imaging can help explain some heterogeneity in COPD. CT 
imaging analysis can detect emphysema visually and quantify the level of emphysema. 
Previous studies have shown quantitative emphysema measured by CT imaging are correlated 
with airflow limitation measured by FEV1 and FVC 6–9. Quantitative CT measures of emphysema 
provide a quantitative assessment of emphysema progression over time.  
 
Inherently, CT measures have a large variability. In the research setting, two common CT 
measures have shown meaningful results: percent emphysema and adjusted lung density 10. 
The percent emphysema is the percentage of low-attenuation areas (i.e. those less than -950 
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Hounsfield Units (HU) on inspiratory CT). The adjusted lung density is the 15th percentile of the 
HU distribution adjusted for predicted total lung volume (also measured by CT) on inspiratory 
CT. Higher percent emphysema and lower adjusted lung density indicate greater severity of 
emphysema.  
 
Etiology of COPD 
 
COPD is a complex disease influenced by multiple environmental and genetic factors. The 
primary environmental risk factor for COPD is cigarette smoking, but individuals vary in their 
susceptibility to the effects of cigarette smoke and only a minority of smokers will ever develop 
COPD. This indicates other factors besides smoking are involved in the development and 
progression of COPD, and these may interact with smoking. 
 
Environmental factors  
 
Cigarette smoking  
Cigarette smoking is considered a primary environmental cause of COPD. In a 25-year 
prospective cohort study of 8,045 individuals, current smokers were 6.3 times more likely to 
develop COPD than never smokers 11. Approximately 80% of COPD deaths are caused by 
smoking, and smokers are 12-13 times more likely to die from COPD than never smokers 12. 
However, a substantial proportion of COPD cases cannot be attributed to smoking alone. The 
majority of population-attributable fraction (PAF) for smoking was less than 80% 13. The 
prevalence of COPD among never smokers ranges from 3 to 15% 14,15. These studies indicate 





There are distinct sex differences in COPD prevalence. It has been known that COPD primarily 
affects men, because men have smoked more than women worldwide 14. However, the 
prevalence of COPD has been increasing in women and the mortality due to COPD is now 
similar between men and women in U.S. 16,17. There is evidence suggesting there may be 
enhanced susceptibility to cigarette smoking in women compared to men, resulting in sex 
differences in COPD. In the National Emphysema Treatment Trial (NETT) study, females had 
fewer pack-years of smoking history than men but had similar severity of COPD 18. In a 
systematic meta-analysis by Gan et al., females had a faster annual rate of decline in lung 
function (measured as FEV1) than males of similar smoking levels 19. The effect of sex on 
COPD development and progression is likely due to a combination of environmental and 




There are also differences in lung function between European Americans (EAs) and African 
Americans (AAs). According to the Centers for Disease Control and Prevention (CDC), the age-
adjusted mortality rate from COPD is 78.1 per 100,000 in EAs and 63.9 per 100,000 in AAs 20. 
However, mortality from COPD is increasing more rapidly among AAs 21 and there is evidence 
that AAs may be more susceptible to the harmful effects of tobacco smoke 22,23. The potential 
impact of these racial differences in COPD development needs further investigation.  
 
Age 
Aging is associated with a progressive decline in lung function even among non-smoking adults 
24. It remains unclear if this change results from a normal aging process or if age reflects the 




Other environmental factors  
A number of additional environmental factors are associated with risk of COPD including chronic 
asthma 25, outdoor air pollution 26, secondhand smoke exposure 27, biomass smoke 28, 
occupational exposure 29,30, diet 31 and tuberculosis 32. However, the specific causal 
relationships among these factors and their individual or combined effects on risk to COPD 
remain unresolved.  
 
Genetic risk factors  
There is evidence of genetic influences on COPD and its related traits. The estimated heritability 
of spirometric measures of lung function (FEV1 and FVC which are used to define COPD) was 
approximately 40% 33. The longitudinal decline in lung function is reported to be moderately 
heritable; the estimated heritability of FEV1, FVC and FEV1/FVC was 0.05, 0.18 and 0.13, 
respectively 34. The heritability of COPD status and quantitative emphysema measured by CT 
scan was estimated as 37% and 25%, respectively 35.  
 
Alpha-1 antitrypsin deficiency 
An established gene influencing risk of COPD is SERPINA1 which encodes serine protease 
alpha-1-antitrypsin (AAT) protein. Mutations in SERPINA1 leads to the hereditary AAT 
deficiency. Homozygosity for the PI*Z allele is the most common cause of AAT deficiency. The 
AAT deficiency follows a Mendelian pattern of inheritance, but there is marked variability in the 
development and severity of COPD among PI*ZZ individuals. This suggests a potential 
SERPINA1-by-environment interaction. However, this gene accounts for only about 1-3% of all 




Genome-wide association studies 
A number of studies have attempted to identify genetic determinants of COPD and its subtypes 
including emphysema quantitatively measured by CT scan using genome-wide association 
studies (GWAS).  
 
Emphysema. Multiple GWASs have been identified for cross-sectional emphysema measures 
based on CT imaging 36–40. Using two quantitative CT measures, percent emphysema and 
adjusted lung density, 7 genetic regions have been identified as associated with cross-sectional 
quantitative emphysema (DLC1, SERPINA1, HHIP, CHRNA3, AGER, SNRPF, BICD1) 36,37,41. 
However, to date, little is known about genetic determinants of progression of emphysema. As 
emphysema is a progressive disease, genetic factors may well be involved in the progression of 
emphysema.  
 
COPD. The most recent and largest GWAS in 35,735 cases and 222,076 controls from the UK 
Biobank and additional studies from the International COPD Genetics Consortium (ICGC) 
identified 82 distinct loci associated with risk of COPD 42. Forty-seven loci had been previously 
identified in GWAS of COPD or population-based measures of lung function 43,44. Thirty-five loci 
were newly identified in this GWAS study. However, the identified variants at these distinct 
genetic regions explained less than 10% of the phenotypic variability on the liability scale.  
 
In an early GWAS of COPD, two genetic loci, containing HHIP on chromosome 4q31 and 
CHRNA3/A5/B4 on 15q25, were identified 45. HHIP (the hedgehog interacting protein) gene 
encodes a regulatory protein in the hedgehog signaling pathway and may influence fetal lung 
development. The 15q25 region has been intriguing but challenging to understand. This 
genomic region contains a gene cluster CHRNA3/A5/B4 related to smoking behavior and 
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nicotine addiction, but it also appears to contain COPD genetic determinants unrelated to 
nicotine addiction – for example, IREB2. Subsequent work also identified FAM13A on 
chromosome 4q22 as a genetic risk factor for COPD 46. Of the genome-wide significant 
association regions for COPD, 7 genes (HHIP, FAM13A, IREB2, AGER, MMP1, MMP12, and 
SFTPD) point to potentially relevant biological processes involved in COPD pathogenesis based 
on a knock-out or transgenic murine model 47.  
 
Lung function. Concurrently, the most recent and largest GWAS identified 279 distinct signals of 
lung function (used to define clinical COPD) in 400,102 individuals of European ancestry from 
the UK Biobank and SpiroMeta Consortium 48. Of these 279 lung function signals, 139 signals 
were newly identified. The study reported an enrichment for genes involved in ciliogenesis 
(including KIAA0753, CDK2 and CEP72).  New signals implicating ITGAV and GDF5, as well as 
stronger evidence for TGFB2 and MFAP2 provided new genetic support for the importance of 
elastic fiber pathways in controlling quantitative measures of lung function and risk to COPD.  
 
Gene-by-Environment Interaction  
 
Broadly, gene-by-environment interaction is defined as that the relationship between phenotype 
and genotype is modified by some environmental risk factors. Gene-by-environment interaction 
is an important component to understand the disease mechanism. There are several important 
applications for evidence of gene-by-environment interactions: 1) it helps to improve the 
understanding of the biology of the disease, 2) it can improve predictions of risk to disease and 




The adverse effects of smoking on risk of COPD may differ by an individual’s genetic 
susceptibility, which raises the possibility of detectable gene-by-smoking interactions using 
genetic data on large samples. However, little is known about gene-by-smoking interactions on 
COPD risk. One robustly replicated interaction is the PI*Z allele (SERPINA1)-by-smoking 
interaction on spirometric measures of lung function 49,50.  
 
Genome-wide approach  
Gene-by-environment interaction studies have been commonly investigated using a single 
marker in candidate genes or at the genome-wide scale. A major challenge to detect and 
replicate gene-by-environment interactions is the much larger sample size required compared to 
conventional GWAS to detect marginal effects of genes 51. To date, genome-wide gene-by-
smoking interaction studies have focused on quantitative measures of lung function 52,53. While 
spirometric measures of lung function are used to diagnose COPD, no genome-wide studies 
have investigated gene-by-smoking interaction on risk of COPD itself. 
 
Polygenic risk score approach  
While the genome-wide approach for identifying potential gene-by-environment interactions can 
help to discover novel gene-by-environment interactions, it is quite challenging to detect and 
replicate such interactions due to a very small effect of each single marker on disease risk in 
general. Several studies have attempted to utilize polygenic risk scores (PRS) to explore gene-
by-environment interactions and found some intriguing findings, such as PRS-by-physical 
activity or PRS-by-sugar consumption interaction on BMI 54–57. PRS is a sum of the number of 
risk alleles for each SNP weighted by the estimated effect size reported from GWASs. An 
empirical study suggested PRS-based tests for interaction can outperform other genome-wide 
10 
 
approaches to detect gene-by-environment interactions, if the interaction effects of each single 
SNP tend to go in the same direction 58. 
 
Recent large-scale GWASs of lung function and COPD have identified multiple genetic loci (279 
signals for lung function and 82 signals for risk to COPD). With these well-established SNPs, 
one can explore the aggregated effect on risk to COPD by constructing PRS based on these 
recognized genetic risk factors and then testing for interaction between PRS and smoking on 
risk of COPD. Previous study investigated the potential interaction between PRS of 26 lung 
function SNPs and smoking on spirometric measures of lung function 58, highlighting the benefit 
of using PRS for identifying interactions missed when studying individual SNPs only.  
 
Motivation and specific aims for this study 
 
Little is known about genetic determinants of progression of emphysema. Identification of 
genetic factors for emphysema progression may identify different or more specific pathways 
than an analysis of overall lung function decline, expand our understanding of the genetics of 
COPD, and perhaps contribute to development of new drug therapies to slow the loss of lung 
density. Despite a well-recognized relationship between cigarette smoking and risk to COPD, 
smoking effects likely vary among individuals due to their genetic makeup, suggesting a 
potential gene-by-smoking interaction. However, to date, gene-by-smoking interactions on risk 
to COPD remain largely unknown. We seek to address these issues through the following 
specific aims:  
 
Aim 1. To examine genetic variants for association with change in quantitative 
emphysema measured by CT imaging from two longitudinal cohort studies: 
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COPDGene and Evaluation of COPD Longitudinally to Identify Predictive Surrogate 
End-points (ECLIPSE) 
 
Aim 2. To identify novel genetic variants for risk of COPD while accounting for 
potential smoking interactions and assess the impact of gene-by-smoking 
interactions on risk of COPD at known COPD and lung function GWAS loci 
 
Aim 3. To examine whether the effect of smoking on COPD risk is modified by a 





The Genetic Epidemiology of COPD (COPDGene) study is a multicenter longitudinal cohort 
enrolling Non-Hispanic Whites (NHW) and African Americans (AA) from multiple sites in the US 
59. The COPDGene recruited subjects between ages of 45 and 80 years with a minimum of 10 
pack-years smoking history at baseline and conducted volumetric inspiratory CT scans of the 
chest. Approximately 5 years later, subjects were asked to return to repeat the chest CT scan 
and detailed questionnaires. CT measures were available on 5,093 subjects COPDGene 
subjects at both visit 1 and visit 2. Subjects were genotyped on the Illumina Human Omni 
Express array (San Diego, CA). Genotyping quality control (QC) was performed following 
previously described guidelines to remove low quality subjects and markers 46,60. Unobserved 
genotypes were imputed using Michigan Imputation Server with the Haplotype Reference 





The Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) is 
a 3-year longitudinal study. The ECLIPSE recruited COPD cases and controls aged 40 to 75 
years with a minimum of 10 pack-years smoking history at baseline. Subjects included in this 
dissertation are self-reported Whites from both American and European sites. Chest CT scan 
was conducted at baseline, after 1 year and after 3 years in the ECLIPSE study. CT measures 
were available on 1,871 subjects who had at least two visits including the baseline. subjects 
were genotyped on the Illumina HumanHap 550 V3 array (San Diego, CA). Genotyping QC was 
performed following previously described guidelines to remove low quality subjects and markers 
46,60. Unobserved genotypes were imputed using Michigan Imputation Server with the HRC 
panel 61.  
 
UK Biobank  
The UK Biobank (UKB) is a population-based large cohort of volunteers where over 500,000 
individuals aged 40-69 were originally recruited 62. Extensive baseline questionnaire data, 
physiologic measures including spirometric measures of lung function, and biologic specimens 
(urine and blood samples) have been obtained. To determine lung function, measures of FEV1 
and FVC were derived from the spirometry volume-time series data, subjected to additional 
quality control based on American Thoracic Society (ATS) / European Respiratory Society 
(ERS) criteria 48,63. Genotyping was performed by using the Axiom UK BiLEVE array and the 




Many recent advances have been made in our understanding of the genetics of COPD. 
However, specific genetic determinants and potential gene-by-environment interactions 
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influencing risk to COPD remain still largely unknown. The overall goal of this dissertation is to 
understand the genetic control of the progression of emphysema over time and to test for gene-
by-smoking interactions on risk to COPD. Improved understanding of the genetics and gene-by-
environment interactions influencing risk to COPD can aid in the discovery of novel therapeutics 
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Chronic obstructive pulmonary disease (COPD), defined by the presence of airflow obstruction 
on spirometry, is the third leading cause of death worldwide 1. Despite the increasing burden of 
the disease, there is no medication that clearly ameliorates the progression of COPD. In 
addition to lung function, progression of this disease can also be assessed by worsening 
emphysema. Emphysema, characterized by the destruction of lung parenchyma, is a key 
component of COPD and associated with increased morbidity and mortality. The presence of 
emphysema is variable among subjects with similar degrees of airflow obstruction. 
 
Advances in computed tomography (CT) imaging provide the opportunity to assess the extent 
and progression of emphysema quantitatively, and to study its related risk factors. The 
progression of emphysema (as determined by quantitative CT imaging) was examined in 
smokers 2, patients with alpha1-antitrypsin deficiency (AATD) 3,4 and smokers with COPD 5. 
Longitudinal change in quantitative emphysema is associated with spirometric measures of lung 
function, severity of COPD and ongoing smoking, and as such has been proposed as a marker 
of response to therapy for COPD 6.  
 
Although smoking is a strong risk factor for emphysema, there is evidence of genetic influences 
on emphysema. The estimated heritability of quantitative emphysema measured by CT scan 
was approximately 30% 7. The longitudinal decline in lung function is reported to be moderately 
heritable (forced expiratory volume in the first second (FEV1): 0.05, forced vital capacity (FVC): 
0.18 and FEV1/FVC: 0.13) 8. Previous genome-wide association studies (GWAS) have 
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identified multiple genetic variants significantly associated with cross-sectional measures of 
quantitative emphysema based on CT imaging 9–13. However, genetic determinants of 
longitudinal change in quantitative emphysema remain largely unknown. Identification of genetic 
factors for emphysema progression may identify different or more specific pathways than an 
analysis of overall lung function decline, expand our understanding of the genetics of COPD and 
contribute to the development of new drug therapies to slow the loss of lung density.  
 
Our study aims to examine genetic variants for association with change in quantitative 
emphysema measured by CT imaging from two longitudinal cohort studies: COPDGene and 
Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). The 
specific objectives of the study are as follows: 1) to conduct GWAS to identify genetic variants 
associated with change in quantitative emphysema measured by CT imaging, and 2) to 
examine the association with change in quantitative emphysema for genetic loci previously 
identified as significantly associated with cross-sectional quantitative emphysema, COPD or 




Study description  
We included current and ex-smokers from the Genetic Epidemiology of COPD (COPDGene) 
study, a multicenter longitudinal cohort enrolling Non-Hispanic Whites (NHW) and African 
Americans (AA), and the Evaluation of COPD Longitudinally to Identify Predictive Surrogate 
End-points (ECLIPSE) study, a 3-year longitudinal study. Detailed descriptions, including 
genotyping quality control, genotyping imputation, and quantitative imaging, have been 




COPDGene recruited subjects between ages of 45 and 80 years with a minimum of 10 pack-
years smoking history at baseline and conducted volumetric inspiratory CT scans of the chest. 
Approximately 5 years later, subjects were asked to return to repeat the chest CT scan and 
detailed questionnaires. CT measures were available on 5,093 subjects COPDGene subjects at 
both visit 1 and visit 2. Among them, we excluded subjects who underwent a lung surgical 
procedure (including lung transplant and/or lung reduction surgery), changed their smoking 
behavior (either quitting smoking or resuming smoking between visits 1 and 2) and/or were 
never smoking control subjects.  
 
ECLIPSE recruited COPD cases and controls aged 40 to 75 years with a minimum of 10 pack-
years smoking history at baseline. Subjects included in this analysis were self-reported White 
ethnicity. Chest CT scan was conducted at baseline, after 1 year and after 3 years in the 
ECLIPSE study. CT measures were available on 1,871 subjects who had at least two visits 
including the baseline. Among them, we excluded subjects who changed their smoking behavior 
during the study.  
 
CT measures 
Volumetric inspiratory CT scans of the chest were acquired at maximal inspiration following 
standardized coaching and practiced breath-holding. Quantitative image analysis was 
performed to generate quantitative measures of emphysema using commercially available 
software Thirona LungQ (Thirona, Nijmegen, The Netherlands) for COPDGene, and Pulmonary 
Workstation 2.0 (VIDA Diagnostics, Coralville, IA, USA) for ECLIPSE. Percent low attenuation 
area (≤-950HU) (%LAA-950) was calculated as the percent of lung voxels with density less than 
-950 Hounsfield Units (HU). Adjusted lung density (ALD) was quantified as the lung density at 
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the 15th percentile of the HU distribution adjusted for the predicted total lung volume on 
inspiratory CT 16. %LAA-950 and ALD were the main CT measures for the analysis and were 
used to calculate the annual change in emphysema. 
 
Genotyping  
In COPDGene, subjects were genotyped on the Illumina Human Omni Express array (San 
Diego, CA) and in ECLIPSE, the Illumina HumanHap 550 V3 array (San Diego, CA). 
Genotyping quality control (QC) was performed following previously described guidelines to 
remove low quality subjects and markers 14,17. Unobserved genotypes were imputed using 
Michigan Imputation Server with the Haplotype Reference Consortium (HRC) panel 18.  
 
Candidate region selection  
To explore the effect of previously reported variants associated with cross-sectional quantitative 
emphysema, COPD, or spirometric measures of lung function on change in quantitative 
emphysema, we curated a list of associated single nucleotide polymorphisms (SNPs) from 
recent published GWASs. Seven loci for cross-sectional quantitative emphysema (DLC1, 
SERPINA1, HHIP, CHRNA3, AGER, SNRPF, BICD1)9,11,19, 85 loci for COPD 20,21 and 279 loci 
for spirometric measures of lung function (FEV1, FVC, FEV1/FVC and Peak expiratory flow 
(PEF)) were included in the analysis 22. We selected the most significant SNP for each genetic 
locus. SNPs for cross-sectional quantitative emphysema, COPD and lung function are listed in 
Supplementary Table 1.1. Given the small effects of individual genetic variants, we 
hypothesized that a polygenic risk score (PRS) comprised of the combined set of variants might 
be associated with cross-sectional quantitative emphysema and the annual change in 
emphysema. For the 279 SNPs previously associated with lung function mostly identified in 
24 
 
European ancestry, we generated a PRS by summing the number of risk alleles for each SNP 
with the weight of the FEV1/FVC effect size, as previously described 22, in our study population. 
 
Statistical analysis  
With two quantitative emphysema measures, %LAA-950 and ALD, we calculated the annual 
change as the difference in emphysema measure between the latest visit and baseline divided 
by the duration of follow-up in years. In COPDGene, with two time-points, the change in 
emphysema was generated by the difference between the second visit and baseline. In 
ECLIPSE where there were three time points available for CT measures, we calculated the 
difference between the latest visit and baseline for subjects with at least two measures.  
 
We performed linear regression on each phenotype adjusted for age, sex, pack-years, smoking 
status (continued current/former smokers), change in scanner make, and principal components 
of genetic ancestry using EPACTS software (version 
3.3, http://genome.sph.umich.edu/wiki/EPACTS/) stratified by race. To reduce the outlier effects 
and obtain a more normal distribution of outcome measures, the annual change in %LAA-950 
and ALD were inverse-normal transformed. To combine results from COPDGene NHW, 
COPDGene AA, and ECLIPSE Whites, a fixed effect meta-analysis with an inverse variance 
weighting was conducted using the METAL software (http://csg.sph.umich.edu/abecasis/metal/) 
23. To examine effects of PRS on baseline emphysema and the annual change in emphysema, 







Basic characteristics of subjects from each study are shown in Table 1.1. The sample size 
included 3,030 NHW and 1,158 AA from COPDGene and 1,397 from ECLIPSE. Follow-up on 
average was approximately 5.5 years among COPDGene subjects and 2.6 years among 
ECLIPSE subjects. In both cohorts, the mean annual change in %LAA-950 was positive and 
mean annual change in ALD negative, consistent with an overall progression in emphysema, 
while the variance of both measures was quite large. The average annual change in %LAA was 
0.02 (0.71) in NHW and 0.10 (0.54) in AA from COPDGene, and 0.59 (2.13) from ECLIPSE. 
The average annual change in ALD was -0.04 (2.05) in NHW and -0.22 (2.27) in AA from 
COPDGene and -1.27 (3.63) from ECLIPSE. At baseline, subjects with %LAA-950 > 5% were 
present at higher in ECLIPSE (79.6%) than in COPDGene (NHW (34.4%) and AA (16.2%)).  
 
GWAS summary results 
In the genome-wide association analysis, we considered a meta-analysis of all subjects as our 
primary analysis. No genetic variants reached genome-wide significance (P<5e-08). Eighteen 
loci for change in %LAA-950 and 17 loci for change in ALD reached a suggestive significance 
(P<1e-05) level (Supplementary Table 1.2 and Supplementary Figure 1.1). For the 
association with %LAA-950, rs13164530 in the WWC1 gene was most significantly associated 
(P=4.32e-07). For the association with ALD, rs7940672 near the WEE1 gene was most 
significantly associated (P=2.74e-06).  
 
From the meta-analysis of European ancestry subjects (3,030 COPDGene NHW and 1,397 
ECLIPSE Whites), 18 loci for change in %LAA-950 and 20 loci for change in ALD reached a 
suggestive significance level (P<1e-05) (Supplementary Table 1.3). rs115047317 near the 
NXPH2 gene achieved borderline genome-wide significance for change in %LAA-950 (P=9.31e-
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08) and rs146580149 near the LRIG2 loci was most significantly associated with change in ALD 
(P=1.04e-06). Among 1,158 AA from COPDGene, 44 loci for change in %LAA-950 and 27 loci 
for change in ALD yielded suggestive significance (P<1e-05). rs146932748 in the CAB39L gene 
and rs6733971 near the ASB3 gene were most significantly associated with change in %LAA-
950 (P=1.97e-07) and with change in ALD (P=1.46e-07), respectively.  
 
Candidate SNP look-up  
To examine candidate SNPs, we used the meta-analysis of European ancestries (3,030 
COPDGene NHW and 1,397 ECLIPSE Whites). We curated 360 SNPs, in total, each previously 
reported to be associated with cross-sectional quantitative emphysema, COPD or spirometric 
measures of lung function. We used a Bonferroni corrected p-values (P=1.39e-04) as a 
measure of statistical significance.  
 
None of the SNPs previously associated with cross-sectional quantitative emphysema were 
significantly associated with the annual change in emphysema. However, for SNPs previously 
reported to be associated with COPD and spirometric measures of lung function, the variant in 
the DSP gene, rs2076295, was associated with the annual change in %LAA-950 (risk allele=T, 
β (SE) =0.09 (0.02), P=3.79e-05) (Table 1.2). This variant was also associated, albeit at 
reduced significance, with the annual change in ALD (β (SE) = -0.06 (0.02), P=2.88e-03). In the 
original scale of outcome measures (without inverse normal transformation), for each risk allele 
the annual change in %LAA-950 increased by 0.06% (SE=0.02, P=7.74e-04) and the annual 
change in ALD decreased by 0.15 g/L (SE=0.05, P=2.06e-03) (Supplementary Table 1.5). In 
AA subjects from COPDGene, this variant was not significantly associated (%LAA-950; 
P=8.30e-01, ALD: P=9.45e-01). In the stratified analyses by COPD status (COPD case defined 
as Global Initiative for Obstructive Lung Disease (GOLD) criteria >=2) and presence of 
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emphysema defined as %LAA-950>5%, this association was still significant and the direction 
was consistent across COPD status and presence of emphysema (Supplementary Tables 1.4 
and 1.5 and Supplementary Figures 1.2 and 1.3). Other variants that approached significance 
(P<0.05) for change in either %LAA-950 or ALD traits are shown in Table 1.2. 
 
Association of lung function polygenic risk score  
The association between PRS based on spirometric measures of lung function and the annual 
change in emphysema was examined in European ancestry subjects (3,030 COPDGene NHW 
and 1,397 ECLIPSE Whites). Scatter plots between the weighted PRS and quantitative 
measures of emphysema for each study are shown in Figure 1.1. For all study populations, 
higher PRS correlated with higher levels of emphysema at baseline. The adjusted mean annual 
change in %LAA-950 in the highest decile was 0.02% (SE=0.06, P=0.66) and 0.45% (SE=0.25, 
P=0.07) higher than that seen in the lowest decile in COPDGene NHW and ECLIPSE Whites, 
respectively (data not shown). The adjusted mean annual change in ALD in the highest decile 
was 0.25 g/L (SE=0.16, P=0.12) and 0.49 g/L (SE=0.43, P=0.26) lower than that seen in the 
lowest decile in COPDGene NHW and ECLIPSE Whites, respectively (data not shown). 
 
We observed a significant association of annual change in emphysema with weighted PRS in 
European ancestry subjects (Table 1.3). The weighted PRS was positively associated with the 
annual change in %LAA-950 (β (SE) =0.0025 (0.0012), P=4.03e-02) and showed a trend toward 
negative association with the annual change in ALD (β (SE) = -0.0021 (0.0012), P=7.31e-02). In 
the original scale of outcome measures (without inverse normal transformation), per one unit 
increase in the weighted PRS, %LAA-950 annually increased by 0.001% (SE=0.001, P=2.13e-
01) and ALD annually decreased by 0.0055 g/L (SE=0.0027, P=4.16e-02) (Supplementary 






This is the first GWAS investigating change in emphysema quantitatively measured by CT 
imaging. We conducted a GWAS to identify variants associated with annual change in 
quantitative emphysema measured by CT scans and examined effects of variants previously 
associated with cross-sectional quantitative emphysema, COPD and spirometric measures of 
lung function on the annual change in emphysema from two large cohorts, COPDGene and 
ECLIPSE. None of SNPs yielded genome-wide significance. However, in our candidate region 
analysis, we identified significant associations of a variant in DSP and a PRS based on 
spirometric measures of lung function with the annual change in emphysema in European 
ancestry.  
 
Interestingly in our candidate region analysis, a variant in the DSP gene (rs2076295 T>G) was 
associated with annual change in %LAA-950, passing the Bonferroni corrected significance. 
The effect size was similar across studies of European ancestry. This finding is particularly 
interesting since rs2076295 is associated with COPD (risk allele=T, P=4.95e-08, OR (95% CI) 
=1.11(1.07-1.15)) 21 and a spirometric measure of lung function (FEV1/FVC ratio) (risk allele=T, 
P=6.95e-23, β (SE) = -0.02 (0.002)) 22, as well as idiopathic pulmonary fibrosis (risk allele=G, 
P=1.14E-16, OR (95% CI) =1.43(1.32-1.55)) 24. The T allele of rs2076295 is associated with 
greater progression of emphysema, higher risk of COPD, and lower lung function, but has a 
protective effect on pulmonary fibrosis.  
 
rs2076295 is intronic to the DSP gene. The DSP gene encodes desmoplakin, a major protein in 
desmosomes which are critical to cell-cell adhesion 25. Desmosomes mechanically connect cells 
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and stabilize tissue architecture 26. Desmosomes are essential in cell proliferation, 
differentiation, migration, morphogenesis, and apoptosis 26. Mutations in DSP have been linked 
to several Mendelian syndromes involving palmoplantar keratoderma 27, left ventricular 
cardiomyopathy 27, familial arrhythmogenic right ventricular dysplasia 28, and lethal ancantholytic 
epidermolysis bullosa 29.  The DSP gene is highly expressed in the airway epithelia 30. 
rs2076295 in the DSP gene is associated with differential gene expression of idiopathic 
pulmonary fibrosis in human lung 24,30. This region was not previously reported to be associated 
with quantitative emphysema in cross-sectional studies. Thus, whether this association 
represents true progression of emphysema or (for the opposite allele) development of fibrosis, 
or both needs confirmation by further studies.  
 
To jointly examine the effect of 279 SNPs of lung function on the annual change in quantitative 
emphysema, we applied a previously constructed PRS weighted by FEV1/FVC effect sizes in 
European ancestry 22. The PRS of lung function was strongly associated with baseline 
emphysema. These findings are consistent with the strong correlation between emphysema and 
lung function. In addition, we found suggestive evidence that individuals with higher PRS 
showed more rapid emphysema progression. Subjects in the highest decile of PRS showed a 
trend toward greater emphysema progression than those in the lowest decile, even though it 
was not statistically significant (P>0.05). Our findings suggest that genetic variants associated 
with cross-sectional lung function might affect development and progression of emphysema, 
and to our knowledge, are the first description of an association of a genetic risk score with 




Our study showed differences in spirometry grade and emphysema measures between two 
studies, COPDGene and ECLIPSE (Table 1.1). It may be due to the different imaging protocols; 
in COPDGene, volumetric inspiratory CT acquisitions were obtained at 200mAs 31, and in 
ECLIPSE 32 all subjects underwent a low-dose volumetric inspiratory CT scan at 40mAs. In 
addition, ECLIPSE included a higher percentage of COPD subjects than COPDGene.  
 
Despite our finding in our candidate region analysis, we did not find significant variants in the 
genome-wide analysis. The failure to identify novel genome-wide significant variants is likely 
due to several factors. First, CT measures to quantify the extent of the emphysema inherently 
have large variation 33. While previous successful GWASs for cross-sectional quantitative 
emphysema used the same CT measures as our current study 9,10, and previous epidemiologic 
studies have found significant longitudinal associations of ALD with severity of COPD 2, our 
sample size was smaller than these prior studies, and likely effect sizes for longitudinal change 
in emphysema are considerably smaller than for cross-sectional genetic association or 
epidemiologic analyses. In a genome-wide setting, more accurate CT emphysema measures 
may be needed to detect the genetic variants with relatively small effect size associated with 
longitudinal change in emphysema. Second, the follow-up period in our study may be too short 
to capture the natural history of emphysema in adults. Our follow-up period (approximately 5.5 
years in COPDGene and 2.6 years in ECLIPSE) is sufficient to show emphysema progression, 
showing an increase in %LAA-950 and decrease in ALD, but very short in the context of the 
natural history of emphysema. To estimate the true emphysema trajectory in adults, such a 
follow-up period may not be sufficient. The emphysema progression in our population may have 
an episodic rather than gradual pattern of progression, which could interfere with our ability to 
detect genetic associations. Also, the observed annual change in emphysema may be 
influenced by the regression to the mean due to the short follow-up period and the 
31 
 
measurement error of CT measures. Longer follow-up may provide more accurate data to 
estimate the emphysema progression. Third, our study populations were enriched for COPD 
patients. Though we observed emphysema progression in our population, to measure the true 
emphysema trajectory, normal subjects without lung abnormalities at baseline may be required 
to detect the genetic variants associated with emphysema progression. Fourth, emphysema 
progression may be less heritable than cross-sectional quantitative measures of emphysema. 
Traits of progression (as demonstrated by the heritability of cross-sectional lung function, versus 
progression 8 ) are likely to be less heritable than ones of development.  
 
Genetic determinants of emphysema progression remain poorly understood. This is the first 
GWAS investigating change in quantitative emphysema measured by CT imaging. No genetic 
variants were associated with annual change in emphysema at genome-wide significance. 
Further study with larger sample sizes and longer follow-up periods may be required to identify 
genetic determinants of emphysema progression. However, we observed a significant 
association of a DSP variant, previously reported in idiopathic pulmonary fibrosis, COPD and 
spirometric measures of lung function, with change in quantitative emphysema over time. This 
finding represents the first genetic association with emphysema progression measured by CT 
scan. PRS based on spirometric measures of lung function may also predict emphysema 
progression. Additional investigation of the DSP gene, and improved genetic risk scores are 
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Table 1.1. Subject Characteristics 
  COPDGene ECLIPSE 
  NHW AA White 
N 3030 1158 1397 
Age (year) 62.42 (8.35) 54.45 (7.09) 62.78 (7.50) 







Former smokers 2161 (71.3) 242 (20.9) 896 (64.1) 
BMI (kg/m2) 29.08 (5.84) 29.30 (6.69) 26.64 (5.39) 
Spirometry Grade       
PRISm 317 (10.5) 177 (15.4) NA 
Control 1363 (45.1) 645 (56.3) 146 (10.5) 
GOLD I 314 (10.4) 69 ( 6.0) NA 
GOLD II 641 (21.2) 175 (15.3) 533 (38.2) 
GOLD III 312 (10.3) 69 ( 6.0) 551 (39.4) 
GOLD IV 77 ( 2.5) 11 ( 1.0) 167 (12.0) 
Annual change in percent emphysema 0.02 (0.71) 0.10 (0.54) 0.59 (2.13) 
Annual change in adjusted lung density -0.04 (2.05) -0.22 (2.27) -1.27 (3.63) 
Follow-up Period (years) 5.51 (0.71) 5.59 (0.89) 2.56 (0.81) 
Emphysema case (%LAA-950 > 5%) at 
baseline 
1041 (34.4) 188 (16.2) 1112 (79.6) 
Mean (SD) for continuous variable; N (%) for categorical variable; GOLD=Global Initiative 
for Chronic Obstructive Lung Disease; PRISm=Preserved Ratio Impaired Spirometry (FEV1 
< 80% predicted with FEV1/FVC > 0.7); NHW=Non-Hispanic Whites; AA=African 





Table 1.2. Association of previously associated variants with annual change in emphysema in candidate gene analysis  
  Meta-analysis of Whites African Americans 




allele Beta SE P Beta SE P 
%LAA-950 
COPD,Lung function DSP 6 7563232 rs2076295 T G 0.086 0.021 3.79E-05 0.008 0.038 8.30E-01 
Lung function LY86 6 6741932 rs1294417 T C 0.062 0.021 2.83E-03 -0.002 0.041 9.69E-01 
Lung function TGFB2 1 218631452 rs6604614 C G 0.065 0.022 3.82E-03 0.042 0.039 2.85E-01 
Lung function BMP4 14 54419106 rs35107139 C A 0.063 0.022 4.17E-03 -0.056 0.04 1.56E-01 
Lung function GLIS2 16 4361138 rs56104880 C T 0.064 0.022 4.67E-03 -0.009 0.046 8.52E-01 
COPD VGLL4 3 11640601 rs2442776 G A 0.083 0.029 4.90E-03 0.075 0.046 1.04E-01 
Lung function VAPA 18 10078071 rs8089099 A G 0.065 0.023 5.03E-03 0.031 0.058 5.90E-01 
COPD DENND2D 1 111738108 rs629619 T C 0.07 0.026 7.57E-03 -0.06 0.049 2.20E-01 
Lung function CSF2 5 131466629 rs3843503 T A 0.053 0.021 1.17E-02 0.074 0.052 1.57E-01 
Lung function JCAD 10 30268770 rs7914842 G A 0.05 0.021 1.68E-02 0.11 0.047 1.92E-02 
Lung function CCDC91 12 28588242 rs7977418 C T 0.049 0.02 1.80E-02 -0.007 0.041 8.55E-01 
Lung function AFAP1 4 7879027 rs62289340 C T 0.049 0.021 1.82E-02 -0.006 0.049 9.00E-01 
COPD SERP2 13 44842503 rs9525927 A G 0.059 0.026 2.40E-02 0.002 0.052 9.71E-01 
Lung function RPAP1 15 41840238 rs2012453 G A 0.045 0.02 2.77E-02 0.017 0.039 6.57E-01 
COPD SPPL2C 17 43924200 rs12373142 C G 0.055 0.025 3.17E-02 0.026 0.099 7.94E-01 
Lung function SUCLG2 3 67455803 rs4132748 C T 0.048 0.023 3.44E-02 0.005 0.05 9.12E-01 
Lung function RIN3 14 93098339 rs11621587 G C 0.055 0.027 3.88E-02 -0.007 0.105 9.45E-01 
Lung function MET 7 116431427 rs193686 T C 0.045 0.022 4.24E-02 0.008 0.038 8.37E-01 
Lung function SPPL2C 17 43940021 rs79412431 G A 0.052 0.026 4.30E-02 0.054 0.098 5.82E-01 
COPD RIN3 14 93105953 rs72699855 G C 0.053 0.026 4.41E-02 0.018 0.064 7.76E-01 
Lung function LTBP4 19 41117300 rs34093919 G A 0.193 0.096 4.56E-02 NA NA NA 
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Lung function THSD4 15 71803450 rs62015883 T C 0.054 0.027 4.68E-02 -0.003 0.052 9.55E-01 
COPD MMP3 11 102720945 rs626750 G A 0.053 0.027 4.72E-02 0.016 0.043 7.05E-01 
ALD 
COPD,Lung function DSP 6 7563232 rs2076295 T G -0.061 0.02 2.88E-03 -0.003 0.037 9.45E-01 
Lung function GLIS2 16 4361138 rs56104880 C T -0.059 0.022 7.50E-03 -0.06 0.044 1.72E-01 
Lung function THSD4 15 71803450 rs62015883 T C -0.07 0.027 9.01E-03 -0.09 0.05 7.06E-02 
Emphysema SNRPF 12 96260474 rs7957346 C A -0.046 0.02 2.42E-02 -0.027 0.038 4.87E-01 
Lung function CSF2 5 131466629 rs3843503 T A -0.046 0.021 2.46E-02 -0.038 0.05 4.45E-01 
Lung function KIAA2012 2 202970250 rs12997625 C T -0.045 0.02 2.58E-02 0.058 0.043 1.76E-01 
COPD MECOM 3 168746145 rs7642001 G A -0.046 0.021 2.75E-02 0.044 0.042 2.97E-01 
Lung function TGFB2 1 218855029 rs28613267 C G -0.044 0.02 2.82E-02 -0.003 0.038 9.33E-01 
Lung function JCAD 10 30268770 rs7914842 G A -0.045 0.021 2.95E-02 -0.021 0.046 6.48E-01 
Lung function ATAD2B 2 24018480 rs13009582 G A -0.044 0.02 3.05E-02 -0.009 0.041 8.31E-01 
Lung function RPAP1 15 41840238 rs2012453 G A -0.043 0.02 3.17E-02 -0.019 0.038 6.23E-01 
Lung function LTBP4 19 41117300 rs34093919 G A -0.2 0.095 3.49E-02 NA NA NA 
Lung function IGFBP3 7 46448518 rs17232687 C T -0.041 0.02 4.12E-02 0.064 0.047 1.73E-01 
Lung function DEFB136 8 11823332 rs4128298 C T -0.047 0.023 4.17E-02 0.05 0.047 2.83E-01 
Lung function LY86 6 6741932 rs1294417 T C -0.042 0.02 4.18E-02 0.025 0.04 5.32E-01 
Lung function DHDDS 1 26775367 rs9438626 G C -0.049 0.025 4.81E-02 -0.028 0.037 4.42E-01 
Lung function SPAG17 1 118911295 rs35043843 G T -0.048 0.024 4.81E-02 -0.068 0.051 1.88E-01 
Emphysema SERPINA1 14 94844947 rs28929474 T C -0.129 0.066 4.95E-02 NA NA NA 
%LAA-950 = percentage of low-attenuation area less than -950 Hounsfield units; ALD = Adjusted lung density; Chr. = Chromosome; Alt.allele = Alternative allele 
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Table 1.3. Association of lung function polygenic risk score with baseline emphysema and annual change in emphysema  
  Baseline emphysema Annual change in emphysema 
  Beta SE P Beta SE P 
%LAA-950 
Meta-Analysis of Whites 0.0103 0.0011 3.00E-19 0.0025 0.0012 4.03E-02 
COPDGene NHW 0.0109 0.0014 1.39E-15 0.0018 0.0014 2.10E-01 
ECLIPSE White 0.0087 0.0021 4.63E-05 0.0041 0.0022 6.49E-02 
COPDGene AA 0.0056 0.0026 2.98E-02 0.0013 0.0028 6.48E-01 
ALD 
Meta-Analysis of Whites -0.0075 0.0011 2.42E-11 -0.0021 0.0012 7.31E-02 
COPDGene NHW -0.0077 0.0013 8.06E-09 -0.0028 0.0014 4.37E-02 
ECLIPSE White -0.0071 0.0021 8.33E-04 -0.0003 0.0022 8.76E-01 
COPDGene AA -0.0039 0.0024 1.06E-01 0.0016 0.0027 5.54E-01 
Outcome inversely normal transformed; %LAA-950=percentage of low-attenuation area less than -950 Hounsfield units; ALD=Adjusted lung density; NHW=Non-Hispanic Whites; 






















%LAA-950=percentage of low-attenuation area less than -950 Hounsfield units; 
ALD=Adjusted lung density; NHW=Non-Hispanic Whites; AA=African Americans; ECLIPSE= 
Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points; 





Supplementary Table 1.1. List of SNPs for candidate region analysis 
Previously associated trait Nearest gene Chr. Position SNP Risk allele Alt. allele 






Lung function PHF13 1 6678864 rs9661802 C A 0.34 0.35 0.34 
COPD MFAP2 1 17306029 rs9435731 C A 0.48 0.49 0.81 
Lung function MFAP2 1 17308254 rs9435733 T C 0.48 0.49 0.81 
Lung function WNT4 1 22612690 rs12737805 A G 0.79 0.77 0.82 
Lung function DHDDS 1 26775367 rs9438626 G C 0.79 0.81 0.47 
Lung function DHDDS 1 26796922 rs12096239 C G 0.27 0.27 0.13 
Lung function BMP8A 1 39995074 rs755249 T C 0.24 0.24 0.05 
COPD PABPC4 1 40060025 rs76841360 A G 0.23 0.24 0.08 
COPD TESK2 1 45946636 rs4660861 T G 0.44 0.43 0.37 
Lung function FAF1 1 51243374 rs1416685 C G 0.42 0.4 0.56 
COPD C1orf87 1 60913143 rs72673419 C T 0.96 0.95 0.9 
Lung function NFIA 1 60966772 rs72673461 T G 0.96 0.95 0.92 
Lung function NEXN 1 78387270 rs9661687 C T 0.14 0.15 0.28 
Lung function TGFBR3 1 92077097 rs1192415 G A 0.19 0.19 0.2 
Lung function TGFBR3 1 92106637 rs10874851 A C 0.49 0.48 0.85 
Lung function TGFBR3 1 92381483 rs11165787 G A 0.31 0.34 0.11 
Lung function DENND2D 1 111737398 rs9970286 G A 0.69 0.7 0.7 
COPD DENND2D 1 111738108 rs629619 T C 0.19 0.18 0.21 
Lung function SPAG17 1 118911295 rs35043843 G T 0.23 0.22 0.15 
Lung function C1orf54 1 150249101 rs11205354 A C 0.45 0.44 0.85 
Lung function MCL1 1 150547747 rs878471 G A 0.44 0.42 0.69 
Lung function KRTCAP2 1 155137395 rs141942982 G T 0.89 0.89 0.69 
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Lung function RALGPS2 1 178719306 rs4651005 C T 0.7 0.67 0.9 
Lung function HMCN1 1 186090370 rs2146098 A G 0.64 0.64 0.28 
Lung function HMCN1 1 186113852 rs17531405 G C 0.81 0.82 0.96 
Lung function PTPRC 1 198898157 rs10919604 G A 0.41 0.41 0.38 
Lung function NR5A2 1 200069216 rs2816992 A G 0.59 0.59 0.69 
Lung function LMOD1 1 201884647 rs4309038 C G 0.45 0.44 0.25 
Lung function PIK3C2B 1 204426295 rs1008833 G A 0.14 0.15 0.03 
Lung function KCNK2 1 215120596 rs556648 G A 0.77 0.76 0.22 
Lung function TGFB2 1 218521609 rs2799098 A G 0.82 0.83 0.94 
Lung function TGFB2 1 218631452 rs6604614 C G 0.71 0.74 0.43 
COPD TGFB2 1 218689155 rs3009947 C T 0.51 0.53 0.47 
Lung function TGFB2 1 218855029 rs28613267 C G 0.5 0.51 0.46 
Lung function LYPLAL1 1 219483218 rs75128958 G A 0.92 0.91 0.99 
Lung function SLC30A10 1 219853742 rs1338227 G T 0.45 0.45 0.84 
COPD SLC30A10 1 219924894 rs11118406 A T 0.73 0.73 0.4 
Lung function HLX 1 221204299 rs17009288 A C 0.7 0.71 0.72 
Lung function DUSP10 1 221631938 rs12757436 A G 0.33 0.33 0.06 
Lung function CHRM3 1 239857524 rs2355237 A G 0.5 0.51 0.63 
COPD CHRM3 1 239901006 rs11579382 G C 0.56 0.58 0.67 
COPD ASAP2 2 9290357 rs955277 T C 0.62 0.61 0.32 
COPD DDX1 2 15906179 rs10929386 T C 0.52 0.53 0.51 
Lung function DDX1 2 15906854 rs2544536 C T 0.53 0.54 0.54 
Lung function KCNS3 2 18287623 rs55884799 C T 0.18 0.16 0.36 
Lung function KCNS3 2 18570024 rs6751968 A C 0.18 0.18 0.41 
Lung function RDH14 2 18702313 rs13430465 T C 0.08 0.08 0.09 
Lung function ATAD2B 2 24018480 rs13009582 G A 0.54 0.55 0.71 
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Lung function CIB4 2 26842146 rs732990 G C 0.56 0.55 0.33 
Lung function PKDCC 2 42243850 rs4952564 A G 0.69 0.69 0.37 
COPD EML4 2 42433247 rs12466981 T C 0.27 0.28 0.11 
Lung function EFEMP1 2 56096892 rs3791679 A G 0.75 0.76 0.93 
Lung function IL1RL1 2 102926362 rs12470864 G A 0.61 0.62 0.83 
Lung function CCNT2 2 135672187 rs62168891 C T 0.53 0.54 0.3 
Lung function ZEB2 2 145797829 rs1406225 T G 0.29 0.29 0.41 
COPD NR4A2 2 157013035 rs72902175 C T 0.88 0.87 0.96 
Lung function NR4A2 2 157016257 rs72902177 C T 0.88 0.87 0.93 
Lung function RBMS1 2 161276378 rs7424771 A G 0.43 0.45 0.43 
Lung function OSBPL6 2 179260382 rs2304340 A G 0.41 0.4 0.27 
Lung function ITGAV 2 187530520 rs2084448 C T 0.3 0.31 0.22 
Lung function PLCL1 2 199723365 rs1249096 G A 0.43 0.41 0.37 
Lung function SPATS2L 2 201208692 rs985256 C A 0.78 0.79 0.28 
Lung function KIAA2012 2 202970250 rs12997625 T C 0.51 0.52 0.25 
Lung function IGFBP5 2 217614730 rs6435952 A T 0.15 0.14 0.29 
Lung function TNS1 2 218604356 rs4294980 G A 0.21 0.21 0.57 
COPD,Lung function TNS1 2 218683154 rs2571445 G A 0.61 0.6 0.81 
Lung function ASIC4 2 220382700 rs4674407 C T 0.5 0.5 0.59 
Lung function PID1 2 229502197 rs62201738 C A 0.07 0.06 0.06 
COPD PID1 2 229569919 rs16825267 C G 0.93 0.94 0.93 
Lung function ASB1 2 239441308 rs6710301 C A 0.86 0.86 0.74 
Lung function TWIST2 2 239604970 rs6431620 T G 0.77 0.79 0.69 
COPD TWIST2 2 239872704 rs62191105 T C 0.2 0.19 0.04 
Lung function TWIST2 2 239881309 rs4308141 G C 0.2 0.19 0.04 
Lung function C2orf54 2 241844033 rs6437219 C T 0.49 0.49 0.6 
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Lung function BOK 2 242495953 rs6733504 A G 0.54 0.55 0.46 
COPD VGLL4 3 11640601 rs2442776 G A 0.14 0.14 0.23 
Lung function WNT7A 3 13787641 rs2974389 A G 0.43 0.43 0.52 
Lung function RARB 3 25179533 rs73048404 T G 0.87 0.86 0.98 
COPD,Lung function RARB 3 25520582 rs1529672 C A 0.83 0.83 0.81 
Lung function RBMS3 3 29469675 rs17666332 T G 0.71 0.69 0.93 
COPD RBMS3 3 29472412 rs13073544 G C 0.72 0.69 0.81 
Lung function CACNA2D3 3 55152319 rs12715478 A G 0.59 0.59 0.59 
COPD CACNA2D3 3 55158224 rs17759204 A G 0.73 0.71 0.87 
COPD SLMAP 3 57746515 rs62259026 T C 0.24 0.23 0.36 
Lung function SLMAP 3 57879611 rs6445932 G T 0.25 0.24 0.44 
Lung function SUCLG2 3 67455803 rs4132748 C T 0.71 0.71 0.81 
Lung function FOXP1 3 71583177 rs35480566 A G 0.58 0.58 0.8 
Lung function PDZRN3 3 73862616 rs586936 A G 0.41 0.4 0.44 
Lung function DCBLD2 3 98822050 rs12497779 T G 0.24 0.24 0.29 
Lung function COL8A1 3 99420192 rs1610265 T C 0.07 0.07 0.17 
COPD ADCY5 3 123077042 rs4093840 T A 0.54 0.51 0.37 
Lung function EEFSEC 3 127931340 rs2999090 A G 0.88 0.89 0.89 
COPD EEFSEC 3 127961178 rs2955083 A T 0.88 0.89 0.89 
COPD ZBTB38 3 141147414 rs7650602 C T 0.43 0.43 0.7 
Lung function RSRC1 3 158226886 rs12634907 G A 0.33 0.33 0.16 
Lung function BCHE 3 165548529 rs1799807 C T 0.02 0.01 NA 
Lung function MECOM 3 168709843 rs879394 G T 0.77 0.76 0.78 
COPD MECOM 3 168746145 rs7642001 G A 0.62 0.61 0.74 
Lung function MECOM 3 169295436 rs78101726 A G 0.85 0.86 0.87 
Lung function IGF2BP2 3 185503456 rs6780171 A T 0.32 0.31 0.56 
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Lung function AFAP1 4 7879027 rs62289340 C T 0.56 0.56 0.81 
Lung function KDR 4 56012149 rs12331869 A G 0.17 0.18 0.37 
COPD BTC 4 75673363 rs4585380 G A 0.74 0.76 0.75 
Lung function BTC 4 75676529 rs62316310 G A 0.74 0.76 0.75 
Lung function FRAS1 4 79403952 rs11098196 T G 0.52 0.53 0.25 
Lung function FAM13A 4 89855495 rs2609279 C T 0.8 0.8 0.74 
Lung function FAM13A 4 89869078 rs2869966 T C 0.4 0.44 0.59 
COPD FAM13A 4 89883818 rs7671261 A G 0.54 0.57 0.68 
Lung function TET2 4 106133184 rs6533183 C T 0.38 0.36 0.34 
Lung function INTS12 4 106766430 rs11722225 T C 0.93 0.93 0.96 
COPD,Lung function NPNT 4 106819053 rs34712979 G A 0.76 0.73 0.95 
Lung function HHIP 4 145330628 rs13109426 G A 0.4 0.41 0.77 
Lung function HHIP 4 145442364 rs13116999 G A 0.45 0.45 0.21 
COPD HHIP 4 145489098 rs13140176 A G 0.6 0.6 0.9 
Emphysema,Lung 
function 
HHIP 4 145506456 rs13141641 T C 0.59 0.59 0.89 
Lung function HHIP 4 145740898 rs2353940 T C 0.76 0.75 0.95 
Lung function CEP72 5 609661 rs11739847 A G 0.19 0.17 0.03 
Lung function TARS 5 33352738 rs268717 C T 0.08 0.09 0.24 
Lung function NNT 5 43976162 rs4866846 A G 0.17 0.14 0.41 
Lung function FGF10 5 44367221 rs6859730 A T 0.33 0.31 0.72 
Lung function ITGA1 5 52187038 rs12522114 C A 0.73 0.74 0.79 
COPD ITGA1 5 52195033 rs1551943 A G 0.23 0.22 0.07 
Lung function ARL15 5 53444498 rs2441026 T C 0.45 0.49 0.39 
COPD TNPO1 5 72144005 rs34651 C T 0.08 0.08 0.03 
Lung function AP3B1 5 77396400 rs425102 T G 0.76 0.77 0.72 
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Lung function SPATA9 5 95025146 rs987068 C G 0.69 0.71 0.93 
COPD SPATA9 5 95036700 rs153916 T C 0.54 0.56 0.6 
Lung function SRFBP1 5 121410529 rs10059661 C G 0.83 0.83 0.9 
Lung function ADAMTS19 5 128767384 rs17163397 G A 0.12 0.13 0.12 
Lung function CSF2 5 131466629 rs3843503 T A 0.57 0.57 0.82 
COPD HSPA4 5 132439010 rs62375246 A T 0.26 0.27 0.31 
COPD HTR4 5 147854970 rs10037493 C T 0.56 0.59 0.5 
Lung function HTR4 5 147856522 rs7733410 G A 0.56 0.59 0.66 
Lung function ADRB2 5 148206885 rs1800888 T C 0.01 0.01 NA 
Lung function AFAP1L1 5 148652302 rs11952673 G T 0.62 0.61 0.82 
COPD CCDC69 5 150595073 rs979453 A G 0.67 0.66 0.3 
Lung function ADAM19 5 156908317 rs11134766 C T 0.94 0.93 0.99 
COPD ADAM19 5 156937043 rs10866659 G A 0.34 0.35 0.59 
Lung function ADAM19 5 156944199 rs11134789 A C 0.34 0.35 0.57 
Lung function FGF18 5 170901463 rs10059996 T G 0.37 0.39 0.73 
COPD FGF18 5 170901586 rs12519165 T A 0.61 0.6 0.27 
Lung function RASGEF1C 5 179598771 rs79898473 C T 0.32 0.31 0.16 
Lung function LY86 6 6741932 rs1294417 T C 0.45 0.47 0.65 
COPD RREB1 6 7211818 rs1334576 A G 0.41 0.41 0.35 
COPD,Lung function DSP 6 7563232 rs2076295 T G 0.55 0.56 0.5 
Lung function BMP6 6 7720059 rs12198986 A G 0.46 0.45 0.23 
Lung function BMP6 6 7797840 rs10498672 C G 0.83 0.83 0.94 
COPD ID4 6 19842661 rs9350191 C T 0.15 0.14 0.13 
COPD PRL 6 22004909 rs13198656 C T 0.46 0.45 0.82 
Lung function PRL 6 22017543 rs13198081 C G 0.37 0.37 0.33 
Lung function ZSCAN31 6 28301099 rs7752448 A G 0.89 0.9 0.71 
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COPD IER3 6 30713580 rs2284174 C T 0.21 0.22 0.48 
Emphysema,COPD,Lung 
function 
AGER 6 32151443 rs2070600 C T 0.96 0.96 NA 
Lung function HMGA1 6 34188892 rs9689096 A C 0.94 0.94 0.75 
Lung function CDC5L 6 44447598 rs9357446 A G 0.53 0.52 0.83 
Lung function RUNX2 6 45530471 rs12202314 T C 0.68 0.67 0.43 
Lung function RUNX2 6 45622748 rs9472541 T A 0.7 0.71 0.19 
Lung function DST 6 56336406 rs2894837 G A 0.37 0.36 0.63 
Lung function KCNQ5 6 73663814 rs13206405 A C 0.19 0.2 0.13 
COPD ARMC2 6 109266255 rs2806356 T C 0.81 0.8 0.95 
Lung function ARMC2 6 109268050 rs2798641 C T 0.81 0.8 0.95 
COPD RFX6 6 117257018 rs674621 T C 0.68 0.69 0.66 
Lung function CENPW 6 126990392 rs6918725 T G 0.49 0.48 0.68 
Lung function SLC2A12 6 134339265 rs2627237 G A 0.41 0.41 0.48 
Lung function CITED2 6 140271357 rs1102077 C A 0.25 0.25 0.14 
COPD CITED2 6 140280398 rs646695 C T 0.25 0.25 0.16 
Lung function VTA1 6 142560957 rs9385988 G A 0.26 0.25 0.24 
COPD ADGRG6 6 142668901 rs9399401 C T 0.27 0.26 0.39 
Lung function ADGRG6 6 142688969 rs17280293 A G 0.97 0.98 NA 
Lung function ADGRG6 6 142745883 rs7753012 G T 0.31 0.3 0.85 
COPD AMZ1 7 2752152 rs798565 G A 0.72 0.73 0.9 
Lung function C1GALT1 7 7256490 rs4318980 A G 0.42 0.43 0.67 
Lung function AGMO 7 15506007 rs4721442 G T 0.17 0.18 0.13 
Lung function MEOX2 7 15872324 rs4721457 C T 0.15 0.15 0.14 
COPD ITGB8 7 20418134 rs2040732 T C 0.43 0.41 0.34 
Lung function SKAP2 7 26848830 rs559233 C T 0.5 0.5 0.41 
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Lung function HOXA3 7 27182329 rs62454414 T G 0.87 0.86 0.97 
Lung function JAZF1 7 28200097 rs1513272 C T 0.49 0.51 0.75 
Lung function IGFBP3 7 46448518 rs17232687 C T 0.51 0.5 0.19 
Lung function SEMA3D 7 84569510 rs12707691 G C 0.32 0.31 0.14 
COPD ZKSCAN1 7 99630342 rs2897075 C T 0.62 0.63 0.86 
Lung function MCM7 7 99692993 rs2261360 G T 0.75 0.78 0.9 
Lung function MET 7 116431427 rs193686 T C 0.69 0.67 0.6 
Lung function RNF32 7 156127246 rs12698403 A G 0.44 0.43 0.28 
COPD MFHAS1 8 8697658 rs9329170 G C 0.15 0.14 0.26 
Lung function PPP1R3B 8 9018590 rs330939 T G 0.61 0.6 0.74 
Lung function DEFB136 8 11823332 rs4128298 C T 0.28 0.26 0.25 
Emphysema DLC1 8 13054869 rs75200691 G T 0.11 0.12 0.08 
Lung function SULF1 8 70367248 rs7465401 T C 0.72 0.7 0.72 
Lung function HSF1 8 145504343 rs7838717 T C 0.37 0.38 0.11 
Lung function SMARCA2 9 1568941 rs771662 T C 0.34 0.35 0.59 
Lung function GLIS3 9 4120648 rs1570203 A G 0.53 0.54 0.61 
COPD GLIS3 9 4143749 rs10114763 A T 0.58 0.59 0.62 
Lung function SH3GL2 9 18013733 rs7041139 T C 0.32 0.33 0.5 
Lung function ELAVL2 9 23587027 rs1107677 T C 0.48 0.48 0.44 
COPD ELAVL2 9 23588684 rs156394 C T 0.46 0.46 0.5 
COPD RASEF 9 85126163 rs7866939 C T 0.32 0.35 0.58 
Lung function PTCH1 9 98266855 rs28446321 T A 0.91 0.89 0.82 
Lung function ERCC6L2 9 98878881 rs72743974 G A 0.16 0.17 0.15 
Lung function GALNT12 9 101632854 rs57649467 G A 0.62 0.6 0.6 
COPD COL15A1 9 101661650 rs10760580 A G 0.28 0.29 0.1 
Lung function ZNF462 9 109483517 rs1491106 T G 0.37 0.37 0.38 
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Lung function ASTN2 9 119234058 rs10983184 C T 0.36 0.37 0.63 
COPD ASTN2 9 119401650 rs803923 A G 0.54 0.56 0.37 
Lung function IER5L 9 131943843 rs967497 G A 0.7 0.7 0.32 
Lung function QSOX2 9 139100413 rs7024579 T C 0.31 0.3 0.07 
Lung function CARD9 9 139259349 rs4073153 G A 0.43 0.44 0.32 
COPD CDC123 10 12277992 rs7068966 C T 0.48 0.48 0.78 
Lung function CDC123 10 12278021 rs7090277 T A 0.48 0.48 0.78 
Lung function JCAD 10 30268770 rs7914842 G A 0.44 0.44 0.76 
Lung function PARD3 10 34480582 rs1274475 G A 0.62 0.61 0.9 
Lung function JMJD1C 10 64998971 rs7082066 G A 0.81 0.8 0.47 
Lung function MYPN 10 69962954 rs10998018 A G 0.47 0.49 0.28 
Lung function CAMK2G 10 75580014 rs7098573 A G 0.74 0.72 0.54 
Lung function CAMK2G 10 75639578 rs60820984 T C 0.2 0.2 0.13 
Lung function ZNF503 10 77119039 rs1259605 T C 0.75 0.77 0.92 
Lung function LRMDA 10 78312002 rs2637254 G A 0.47 0.48 0.73 
COPD LRMDA 10 78318879 rs2579762 A C 0.51 0.51 0.82 
COPD,Lung function SFTPD 10 81706324 rs721917 G A 0.43 0.44 0.41 
Lung function STN1 10 105639611 rs11191841 C T 0.5 0.5 0.37 
COPD STN1 10 105656874 rs1570221 G A 0.65 0.65 0.84 
Lung function DMBT1 10 124297637 rs4279944 C T 0.85 0.84 0.8 
COPD ARNTL 11 13171236 rs4757118 C T 0.45 0.44 0.83 
Lung function SLC1A2 11 35308988 rs10836366 T C 0.76 0.73 0.73 
Lung function HSD17B12 11 43690717 rs17596617 T C 0.32 0.32 0.37 
Lung function PRDM11 11 45244903 rs10838435 G C 0.85 0.85 0.41 
Lung function EML3 11 62370155 rs71490394 G A 0.63 0.65 0.87 
Lung function ARHGEF17 11 73036179 rs2027761 C T 0.89 0.9 0.66 
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COPD PRSS23 11 86444761 rs117261012 A G 0.85 0.84 0.97 
Lung function PRSS23 11 86448839 rs11234768 T C 0.85 0.84 0.97 
COPD MMP3 11 102720945 rs626750 G A 0.82 0.84 0.73 
Lung function RPUSD4 11 126009500 rs541601 C T 0.81 0.81 0.62 
Lung function FKBP4 12 2908330 rs56196860 C A 0.97 0.97 NA 
Lung function CCND2 12 4243749 rs12811814 T C 0.45 0.46 0.68 
Lung function AEBP2 12 19808912 rs10841302 G C 0.46 0.43 0.22 
COPD CCDC91 12 28320536 rs11049386 T A 0.73 0.73 0.94 
Lung function CCDC91 12 28588242 rs7977418 C T 0.46 0.46 0.3 
Emphysema BICD1 12 32380501 rs10844154 C A 0.56 0.56 0.43 
Lung function SUOX 12 56396768 rs1689510 C G 0.33 0.34 0.12 
Lung function LRP1 12 57527283 rs11172113 C T 0.4 0.42 0.43 
Lung function RASSF3 12 65075332 rs1244869 G T 0.37 0.37 0.23 
Lung function MSRB3 12 65793153 rs12825748 C G 0.32 0.32 0.15 
Lung function HMGA2 12 66409367 rs11176001 C A 0.87 0.87 0.96 
Lung function ALX1 12 85719906 rs56390486 A G 0.29 0.29 0.17 
Lung function CRADD 12 94194890 rs9788269 G A 0.25 0.26 0.14 
Lung function FGD6 12 95554771 rs113745635 C T 0.78 0.76 0.81 
COPD SNRPF 12 96237570 rs7307510 T C 0.19 0.16 0.25 
Lung function SNRPF 12 96242109 rs7970544 T G 0.19 0.16 0.06 
Emphysema SNRPF 12 96260474 rs7957346 C A 0.43 0.4 0.37 
Lung function IGF1 12 102824921 rs972936 T C 0.27 0.26 0.37 
Lung function TBX5 12 114669870 rs2701110 C A 0.85 0.84 0.88 
Lung function TBX3 12 115201436 rs10850377 A G 0.34 0.33 0.17 
Lung function TBX3 12 115501127 rs35505 A G 0.69 0.68 0.87 
COPD MED13L 12 115947901 rs7958945 G A 0.36 0.37 0.69 
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Lung function SMIM2 13 44820608 rs9533803 C T 0.79 0.78 0.92 
COPD SERP2 13 44842503 rs9525927 A G 0.81 0.82 0.83 
Lung function KCNRG 13 50707087 rs2812208 C G 0.02 0.02 NA 
Lung function KLHL1 13 71647588 rs803765 A C 0.35 0.35 0.17 
Lung function NDFIP2 13 80467235 rs4885681 C T 0.28 0.27 0.7 
Lung function DOCK9 13 99665512 rs11620380 A C 0.11 0.11 0.03 
Lung function MYO16 13 109918493 rs9634470 T C 0.75 0.76 0.81 
Lung function HAUS4 14 23429729 rs1951121 G T 0.4 0.42 0.48 
Lung function BMP4 14 54346010 rs74053129 A G 0.1 0.09 0.03 
Lung function BMP4 14 54419106 rs35107139 C A 0.42 0.4 0.5 
Lung function VRTN 14 74817418 rs10141786 A G 0.42 0.42 0.19 
Lung function FLRT2 14 84338431 rs1756281 A G 0.7 0.7 0.38 
Lung function TRIP11 14 92512143 rs11160037 A G 0.61 0.63 0.34 
Lung function RIN3 14 93098339 rs11621587 G C 0.81 0.83 0.96 
COPD RIN3 14 93105953 rs72699855 G C 0.81 0.83 0.9 
Emphysema SERPINA1 14 94844947 rs28929474 T C 0.02 0.03 NA 
Lung function BMF 15 40397191 rs34245505 C G 0.81 0.79 0.96 
Lung function IVD 15 40716253 rs2304645 G C 0.49 0.48 0.78 
Lung function CHAC1 15 41255396 rs4924525 A C 0.51 0.52 0.36 
Lung function RPAP1 15 41840238 rs2012453 G A 0.57 0.57 0.49 
Lung function MGA 15 41953211 rs56383987 T C 0.05 0.06 NA 
Lung function COPS2 15 49409527 rs79234094 A G 0.27 0.26 0.08 
Lung function FAM227B 15 49706145 rs35251997 T A 0.07 0.07 0.05 
COPD DTWD1 15 49984710 rs72731149 C G 0.07 0.07 0.24 
Lung function USP3 15 63866877 rs62012772 C T 0.18 0.19 0.03 
Lung function AAGAB 15 67491274 rs12917612 A C 0.23 0.22 0.08 
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COPD,Lung function THSD4 15 71612514 rs1441358 T G 0.68 0.65 0.49 
Lung function THSD4 15 71803450 rs62015883 T C 0.18 0.17 0.17 
Lung function REC114 15 73833600 rs7176074 T G 0.05 0.05 0.36 
Emphysema,COPD CHRNA3 15 78898932 rs55676755 G C 0.37 0.42 0.17 
Lung function SH3GL3 15 84274591 rs1896797 A G 0.49 0.48 0.84 
COPD ADAMTSL3 15 84392907 rs10152300 G A 0.23 0.23 0.07 
Lung function CLUAP1 16 3583173 rs3751837 C T 0.79 0.79 0.75 
Lung function GLIS2 16 4361138 rs56104880 C T 0.31 0.29 0.68 
Lung function GRIN2A 16 10136889 rs11074547 T G 0.74 0.72 0.61 
COPD TEKT5 16 10709013 rs56134392 C T 0.34 0.35 0.63 
Lung function TEKT5 16 10740982 rs78442819 C G 0.2 0.22 0.04 
Lung function SH2B1 16 28870962 rs12446589 A G 0.39 0.4 0.09 
Lung function TENT4B 16 50188929 rs76219171 A G 0.06 0.05 0.02 
Lung function FTO 16 53935407 rs35420030 T C 0.95 0.95 0.99 
COPD TEPP 16 58022625 rs8044657 A G 0.09 0.08 0.3 
Lung function MMP15 16 58063513 rs11648508 G T 0.3 0.3 0.54 
Lung function WWP2 16 69891510 rs8047194 G T 0.5 0.52 0.48 
COPD CFDP1 16 75340231 rs4888379 A T 0.41 0.4 0.7 
Lung function CFDP1 16 75411445 rs11858992 A C 0.41 0.4 0.64 
Lung function WWOX 16 78225633 rs2345443 A G 0.31 0.31 0.17 
Lung function FOXF1 16 86403821 rs12918140 G C 0.9 0.89 0.97 
Lung function MTHFSD 16 86579223 rs6539952 A C 0.25 0.24 0.61 
Lung function ATP2A3 17 3882613 rs8082036 C G 0.51 0.51 0.79 
Lung function PITPNM3 17 6469793 rs4796334 A G 0.49 0.51 0.31 
Lung function CLDN7 17 7163350 rs1215 A G 0.85 0.85 0.96 
Lung function TNFSF12 17 7448457 rs4968200 G C 0.86 0.86 0.44 
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Lung function NCOR1 17 16030520 rs34351630 T C 0.45 0.46 0.7 
Lung function SSH2 17 28072327 rs2244592 A G 0.47 0.47 0.2 
COPD EFCAB5 17 28413129 rs8080772 C T 0.35 0.35 0.09 
Lung function ATAD5 17 29210595 rs62070648 A G 0.27 0.27 0.1 
COPD RPL23 17 36835079 rs34727469 T C 0.13 0.14 0.04 
Lung function RPL23 17 36915540 rs35246838 C T 0.13 0.13 0.03 
Lung function FBXL20 17 37504933 rs8069451 C T 0.27 0.25 0.7 
COPD THRA 17 38218773 rs62065216 A G 0.42 0.45 0.26 
COPD SPPL2C 17 43924200 rs12373142 C G 0.79 0.78 0.96 
Lung function SPPL2C 17 43940021 rs79412431 G A 0.79 0.78 0.95 
Lung function SKAP1 17 46552229 rs12945803 C T 0.22 0.22 0.14 
Lung function ANKFN1 17 54195453 rs28519449 T C 0.39 0.4 0.2 
Lung function BCAS3 17 59286644 rs8068952 G C 0.22 0.22 0.83 
Lung function DDX5 17 62497964 rs77672322 T C 0.02 0.03 NA 
Lung function SMURF2 17 62686730 rs11653958 A G 0.74 0.74 0.93 
Lung function KCNJ2 17 68976415 rs6501431 T C 0.78 0.76 0.83 
Lung function SOX9 17 69201811 rs6501455 G A 0.47 0.47 0.27 
COPD SOX9 17 69216687 rs11655567 T C 0.53 0.53 0.71 
Lung function SOX9 17 69371318 rs996865 C T 0.92 0.91 0.78 
Lung function LLGL2 17 73525670 rs9892893 T G 0.26 0.27 0.33 
Lung function ASPSCR1 17 79952944 rs59606152 C T 0.89 0.88 0.95 
Lung function MTCL1 18 8801351 rs513953 G A 0.74 0.75 0.48 
COPD MTCL1 18 8808464 rs647097 T C 0.72 0.73 0.61 
Lung function VAPA 18 10078071 rs8089099 A G 0.27 0.27 0.13 
Lung function GATA6 18 19816712 rs1985511 A T 0.46 0.45 0.43 
Lung function RBBP8 18 20234336 rs11082051 G A 0.49 0.49 0.86 
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Lung function CABLES1 18 20708321 rs9947743 A G 0.79 0.79 0.93 
Lung function RIOK3 18 21074255 rs303752 A G 0.4 0.4 0.11 
Lung function HRH4 18 22290711 rs1668091 T C 0.69 0.68 0.64 
Lung function SLC14A2 18 42827898 rs9807668 C T 0.91 0.9 0.97 
Lung function DCC 18 51022606 rs12607758 C T 0.4 0.4 0.67 
Lung function TCF4 18 53566471 rs2202572 C A 0.67 0.68 0.58 
Lung function QTRT1 19 10819967 rs11085744 T C 0.56 0.59 0.66 
Lung function TSHZ3 19 31829613 rs9636166 C A 0.14 0.12 0.09 
Lung function ZFP82 19 36881643 rs2967516 A G 0.72 0.71 0.7 
Lung function LTBP4 19 41117300 rs34093919 G A 0.99 0.99 NA 
COPD CYP2A6 19 41339896 rs12459249 C T 0.68 0.71 0.68 
COPD DMWD 19 46294136 rs72626215 G A 0.73 0.75 0.89 
Lung function BMP2 20 6626218 rs2145272 G A 0.36 0.36 0.34 
Lung function JAG1 20 10745545 rs6032942 G C 0.76 0.76 0.84 
Lung function ABHD12 20 25282608 rs2236180 C T 0.19 0.2 0.07 
Lung function KIF3B 20 30858967 rs4413223 A G 0.17 0.17 0.5 
Lung function GDF5 20 34025756 rs143384 A G 0.58 0.58 0.13 
Lung function EYA2 20 45486817 rs12481092 T C 0.26 0.27 0.12 
Lung function SLC2A4RG 20 62372706 rs4809221 A G 0.7 0.72 0.71 
Lung function MRPS6 21 35368402 rs12627254 G T 0.87 0.87 0.96 
COPD KCNE2 21 35661745 rs2096468 A C 0.44 0.44 0.6 
Lung function KCNE2 21 35675966 rs62213732 C T 0.37 0.37 0.52 
Lung function MICAL3 22 18448113 rs1978968 T C 0.22 0.21 0.09 
COPD MICAL3 22 18488883 rs9617650 C G 0.2 0.19 0.2 
Lung function SCARF2 22 20790723 rs9610955 C G 0.18 0.19 0.05 
Lung function MN1 22 28181399 rs2283847 T C 0.55 0.56 0.34 
56 
 
COPD SYN3 22 33335386 rs73158393 G C 0.26 0.24 0.06 
Lung function PPP6R2 22 50867711 rs113111175 T C 0.11 0.1 0.03 





Supplementary Table 1.2. SNPs associated with annual change in emphysema at the suggestive significance (P < 1e-05) 
in Meta-analysis of all subjects 
  COPDGene NHW COPDGene AA ECLIPSE Whites Meta-analysis of All subjects 
Nearest 
gene Chr. Position SNP 
Risk 
allele Alt.allele RAF Beta SE P RAF Beta SE P RAF Beta SE P Beta SE P 
Change in %LAA-950 
WWC1 5 16772418
6 
rs13164530 T G 0.136 0.132 0.035 1.96E-
04 
0.068 0.172 0.079 3.01E-
02 
0.144 0.144 0.054 0.00761 0.14 0.028 4.32E-07 
KLK15 19 51345568 rs2659051 G C 0.779 0.128 0.03 2.62E-
05 
0.821 0.163 0.059 5.52E-
03 
0.786 0.053 0.047 0.25447 0.115 0.023 8.92E-07 
SP8 7 21028614 rs73269804 A C 0.925 0.134 0.047 4.07E-
03 
0.722 0.148 0.043 6.77E-
04 
0.929 0.147 0.072 0.04261 0.142 0.029 9.92E-07 
PRR25 16 867299 rs79237026 A C 0.024 0.171 0.088 5.16E-
02 
0.087 0.263 0.074 3.55E-
04 
0.02 0.565 0.174 0.00121 0.258 0.054 1.58E-06 
NSD2 4 1960600 rs7377981 C T 0.927 0.126 0.048 8.12E-
03 
0.981 0.382 0.156 1.44E-
02 
0.936 0.291 0.077 0.00017 0.185 0.039 2.43E-06 
RBMS3 3 29338495 rs6799108 C T 0.082 0.098 0.044 2.75E-
02 
0.172 0.138 0.051 6.98E-
03 
0.08 0.242 0.068 0.00039 0.14 0.03 3.30E-06 
ALDH1B1 9 38395940 rs2228094 T C 0.04 0.183 0.065 4.72E-
03 
0.122 0.163 0.063 9.93E-
03 
0.04 0.279 0.103 0.00667 0.19 0.041 4.36E-06 
CBFA2T3 16 88961129 rs11623308
4 
G T 0.016 0.056 0.098 5.69E-
01 
0.075 0.412 0.081 4.42E-
07 





A G 0.91 0.15 0.043 4.90E-
04 
0.93 0.093 0.079 2.41E-
01 
0.91 0.187 0.067 0.00518 0.149 0.033 5.76E-06 
MDGA2 14 48377425 rs14425102
8 
T G 0.975 0.214 0.08 7.28E-
03 
0.92 0.282 0.073 1.15E-
04 
0.98 0.049 0.132 0.70836 0.223 0.05 8.00E-06 
TXNRD1 12 10461222
5 
rs12303096 A G 0.944 0.112 0.052 3.25E-
02 
0.764 0.162 0.045 3.59E-
04 
0.942 0.14 0.08 0.08108 0.141 0.032 8.13E-06 
OR2Y1 5 18014216
3 
rs7717059 T G 0.726 0.084 0.027 2.23E-
03 
0.424 0.093 0.04 1.95E-
02 
0.731 0.094 0.042 0.02455 0.088 0.02 8.37E-06 
TIAM1 21 32627826 rs2833351 C G 0.916 0.135 0.044 2.22E-
03 
0.665 0.129 0.042 2.23E-
03 





G A 0.987 0.262 0.11 1.74E-
02 
0.989 0.569 0.211 7.26E-
03 
0.987 0.53 0.172 0.00215 0.377 0.085 9.30E-06 
CREB5 7 28555835 rs216707 T A 0.349 0.09 0.027 7.44E-
04 
0.432 0.062 0.041 1.33E-
01 
0.329 0.107 0.042 0.01037 0.088 0.02 9.46E-06 
PTPRD 9 8975175 rs10977419 C T 0.102 0.179 0.041 1.24E-
05 
0.024 0.102 0.135 4.50E-
01 
0.098 0.081 0.063 0.19967 0.147 0.033 9.63E-06 
C11orf74 11 36738257 rs11033758 A G 0.568 0.088 0.025 3.65E-
04 
0.908 0.135 0.067 4.38E-
02 
0.575 0.075 0.041 0.06759 0.089 0.02 9.74E-06 
ZHX2 8 12367420
4 
rs68133336 G A 0.571 0.063 0.025 1.25E-
02 
0.747 0.086 0.046 6.18E-
02 
0.564 0.136 0.039 0.00048 0.085 0.019 9.88E-06 
Change in ALD 










0.054 0.0059 -0.116 0.025 2.74E-06 










0.051 0.00957 -0.116 0.025 3.32E-06 










0.128 0.41434 -0.227 0.049 3.41E-06 
NDUFA10 2 24086675
7 

























0.072 0.00775 -0.151 0.033 4.71E-06 










0.051 0.03474 -0.117 0.026 4.75E-06 
FRK 6 11561888
4 










0.04 0.15286 -0.089 0.02 5.18E-06 
RIMBP2 12 13122614
2 










0.038 0.16675 -0.083 0.018 5.85E-06 










0.125 0.71109 -0.191 0.042 6.34E-06 
BRINP1 9 12230458
2 










0.058 0.00059 -0.135 0.03 6.82E-06 
RTL1 14 10131087
9 










0.046 0.05772 -0.102 0.023 7.56E-06 
IGSF9B 11 13384331
5 








0.324 -0.12 0.047 0.01083 -0.096 0.022 8.67E-06 








0.803 -0.08 0.046 0.08459 -0.1 0.022 8.70E-06 
NXN 17 874466 rs11361121
5 










0.101 0.32919 -0.205 0.046 8.84E-06 
MCC 5 11282416
6 










0.04 0.23764 -0.085 0.019 8.98E-06 










0.068 0.01715 -0.12 0.027 9.04E-06 
RNF150 4 14182846
9 










0.175 0.00085 -0.39 0.088 9.31E-06 





Supplementary Table 1.3. SNPs associated with annual change in emphysema at the suggestive significance (P < 1e-05) 
in Meta-analysis of Whites 
 COPDGene NHW ECLIPSE Whites Meta-analysis of Whites COPDGene AA 
Nearest 




allele RAF Beta SE P RAF Beta SE P Beta SE P RAF Beta SE P 
Change in %LAA-950 
NXPH2 2 139581765 rs115047317 G A 0.969 0.375 0.073 2.55E
-07 




NA NA NA NA 
VSTM2A 7 54177112 rs1965517 A G 0.929 0.186 0.048 1.11E
-04 




0.786 0.005 0.047 9.23E
-01 
TENM3 4 182163057 rs78796196 C A 0.982 0.293 0.094 1.80E
-03 




NA NA NA NA 
PDIK1L 1 26439829 rs183758663 A C 0.964 0.251 0.072 4.69E
-04 




NA NA NA NA 
CATSPER4 1 26519293 rs56177125 G A 0.959 0.269 0.062 1.33E
-05 




NA NA NA NA 
CNKSR1 1 26507612 rs35600413 A T 0.967 0.294 0.068 1.65E
-05 




NA NA NA NA 
RAB3A 19 18314266 rs73001430 C A 0.959 0.277 0.068 5.08E
-05 




NA NA NA NA 
SGCD 5 154996354 rs4958830 A T 0.025 0.267 0.083 1.28E
-03 




NA NA NA NA 
WWC1 5 167724186 rs13164530 T G 0.136 0.132 0.035 1.96E
-04 




0.068 0.172 0.079 3.01E
-02 
MSI2 17 55671179 rs76716491 T G 0.012 0.461 0.121 1.37E
-04 




NA NA NA NA 
PLXNA2 1 208806940 rs6685613 T C 0.863 0.142 0.036 6.37E
-05 




0.749 0.011 0.045 8.15E
-01 
LOXL4 10 100053881 rs75822602 T C 0.033 0.321 0.071 5.81E
-06 




NA NA NA NA 
NECTIN2 19 45383037 rs11673139 A T 0.909 0.166 0.043 1.28E
-04 




0.909 0.035 0.077 6.50E
-01 
DCAF6 1 168028674 rs11803859 G A 0.927 0.183 0.048 1.38E
-04 




0.973 0.033 0.127 7.95E
-01 
SEC16B 1 177721831 rs12131792 A G 0.038 0.285 0.064 9.63E
-06 




NA NA NA NA 
NDUFA4 7 10572624 rs149165422 A G 0.984 0.398 0.101 8.91E
-05 




NA NA NA NA 
CENPC 4 67813755 rs1481266 C T 0.028 0.217 0.082 7.91E
-03 




NA NA NA NA 
ZNF839 14 102785629 rs150789694 A C 0.985 0.49 0.114 1.85E
-05 




NA NA NA NA 
Change in ALD 
LRIG2 1 113591452 rs146580149 A G 0.951 -0.198 0.061 1.21E
-03 




NA NA NA NA 
DR1 1 93814700 rs116807672 C T 0.982 -0.497 0.105 2.24E
-06 




NA NA NA NA 
FNBP1L 1 93981950 rs10518536 A G 0.981 -0.482 0.103 3.09E
-06 




NA NA NA NA 
LY96 8 74983233 rs74859713 T C 0.03 -0.344 0.074 3.05E
-06 




0.026 0.088 0.146 5.45E
-01 
FAM135B 8 138579554 rs72728184 T C 0.089 -0.173 0.042 4.58E
-05 








FRK 6 116002717 rs12205186 A T 0.686 -0.113 0.026 1.08E
-05 




0.674 -0.028 0.04 4.89E
-01 
GZMB 14 25120382 rs7154975 G A 0.531 -0.081 0.024 6.87E
-04 




0.726 -0.002 0.043 9.72E
-01 
RNF144B 6 18575300 rs6916983 T C 0.725 -0.09 0.026 6.40E
-04 




0.608 0.022 0.038 5.61E
-01 
TSHZ2 20 51935555 rs200649 T C 0.825 -0.121 0.032 1.47E
-04 




0.904 -0.068 0.065 2.92E
-01 
CCDC18 1 93675574 rs115453772 C G 0.985 -0.463 0.112 3.93E
-05 




NA NA NA NA 
MSI2 17 55671179 rs76716491 T G 0.012 -0.388 0.119 1.09E
-03 




NA NA NA NA 
ADAMTSL1 9 18806785 rs72690583 T C 0.01 -0.327 0.12 6.36E
-03 




NA NA NA NA 
LIMCH1 4 41690410 rs16853485 C T 0.826 -0.109 0.032 5.38E
-04 




0.812 0.008 0.048 8.66E
-01 
RTL1 14 101310879 rs12587062 G A 0.763 -0.119 0.029 3.52E
-05 




0.911 -0.045 0.067 5.05E
-01 
PTPRK 6 128831588 rs150582742 C T 0.034 -0.361 0.075 1.68E
-06 




NA NA NA NA 
ZNF600 19 53280252 rs10414169 A T 0.982 -0.322 0.103 1.69E
-03 




0.786 -0.018 0.054 7.33E
-01 
KSR2 12 118176064 rs4767602 C T 0.106 -0.179 0.041 1.32E
-05 




0.055 0.009 0.092 9.25E
-01 
BRINP1 9 122304582 rs17578200 G C 0.135 -0.115 0.037 1.70E
-03 




0.041 -0.068 0.116 5.57E
-01 
SNCA 4 90718390 rs33978842 G C 0.96 -0.232 0.064 2.69E
-04 




NA NA NA NA 
IFT74 9 27002194 rs145997721 C A 0.035 -0.267 0.068 9.86E
-05 




NA NA NA NA 
%LAA-950=percentage of low-attenuation area less than -950 Hounsfield units; ALD=Adjusted lung density; Chr.=Chromosome; Alt. Allele=Alternative Allele; RAF=Risk allele frequency; NHW=Non-Hispanic Whites; AA=African Americans; 




Supplementary Table 1.4. Association of DSP variant, rs2076295, with annual change in emphysema stratified by COPD 
status and presence of emphysema in European ancestry (Transformed measure) 
 
COPDGene NHW ECLIPSE Whites Meta-analysis of Whites 
Sub-group N Beta SE P N Beta SE P Beta SE P 
Change in %LAA-950 
Overall 3030 0.0842 0.0249 7.50E-04 1397 0.092 0.0386 1.72E-02 0.0865 0.021 3.66E-05 
COPD case 1030 0.0558 0.0439 2.04E-01 1251 0.1027 0.0407 1.16E-02 0.081 0.0298 6.58E-03 
COPD control 1363 0.0888 0.0368 1.60E-02 146 -0.0642 0.1202 5.94E-01 0.0757 0.0352 3.15E-02 
Emphysema case 1041 0.1072 0.0423 1.14E-02 1112 0.0821 0.043 5.67E-02 0.0949 0.0302 1.66E-03 
Emphysema control 1989 0.0786 0.0306 1.04E-02 285 0.2256 0.0894 1.22E-02 0.094 0.029 1.17E-03 
Change in ALD 
Overall 3030 -0.0611 0.0245 1.27E-02 1397 -0.0629 0.0385 1.02E-01 -0.0617 0.0207 2.85E-03 
COPD case 1030 -0.0449 0.043 2.96E-01 1251 -0.0613 0.0405 1.30E-01 -0.0536 0.0295 6.89E-02 
COPD control 1363 -0.0603 0.0364 9.79E-02 146 -0.0867 0.1209 4.74E-01 -0.0625 0.0348 7.30E-02 
Emphysema case 1041 -0.1184 0.0412 4.14E-03 1112 -0.0355 0.0428 4.07E-01 -0.0785 0.0297 8.16E-03 
Emphysema control 1989 -0.0455 0.0306 1.37E-01 285 -0.1855 0.0915 4.37E-02 -0.0596 0.029 4.01E-02 
Outcome inversely normal transformed; %LAA-950=percentage of low-attenuation area less than -950 Hounsfield units; ALD=Adjusted lung density; NHW=Non-Hispanic Whites; 




Supplementary Table 1.5. Association of DSP variant, rs2076295, with annual change in emphysema stratified by COPD 
status and presence of emphysema in European ancestry (Untransformed measure) 
 COPDGene NHW ECLIPSE Whites Meta-analysis of Whites 
Sub-group N Beta SE P N Beta SE P Beta SE P 
Change in %LAA-950 
Overall 3030 0.0523 0.0179 3.57E-03 1397 0.1975 0.0821 1.63E-02 0.0589 0.0175 7.74E-04 
COPD case 1030 0.0503 0.0424 2.35E-01 1251 0.231 0.0904 1.07E-02 0.0829 0.0384 3.08E-02 
COPD control 1363 0.0381 0.0172 2.69E-02 146 -0.1247 0.1229 3.12E-01 0.035 0.017 4.00E-02 
Emphysema case 1041 0.115 0.0472 1.50E-02 1112 0.1971 0.0996 4.82E-02 0.13 0.0427 2.31E-03 
Emphysema control 1989 0.0232 0.0107 3.05E-02 285 0.2279 0.1004 2.40E-02 0.0255 0.0107 1.67E-02 
Change in ALD 
Overall 3030 -0.1311 0.0502 9.14E-03 1397 -0.26 0.1402 6.40E-02 -0.1457 0.0473 2.06E-03 
COPD case 1030 -0.1078 0.0856 2.08E-01 1251 -0.2503 0.1503 9.60E-02 -0.1427 0.0744 5.51E-02 
COPD control 1363 -0.1131 0.0736 1.25E-01 146 -0.3673 0.3699 3.23E-01 -0.1228 0.0722 8.91E-02 
Emphysema case 1041 -0.2716 0.0866 1.75E-03 1112 -0.1696 0.1447 2.41E-01 -0.2447 0.0743 9.87E-04 
Emphysema control 1989 -0.0869 0.0611 1.55E-01 285 -0.7012 0.4059 8.52E-02 -0.1005 0.0604 9.61E-02 
Outcome untransformed; %LAA-950=percentage of low-attenuation area less than -950 Hounsfield units; ALD=Adjusted lung density; NHW=Non-Hispanic Whites; ECLIPSE= 
Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points 
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Supplementary Table 1.6. Association of lung function polygenic risk score with baseline emphysema and annual change 
in emphysema (Untransformed measure) 
  Baseline emphysema Annual change in emphysema 
  Beta SE P Beta SE P 
%LAA-950 
Meta-Analysis of Europeans 0.082 0.0109 6.16E-14 0.0012 0.001 2.13E-01 
COPDGene NHW 0.0793 0.0119 3.53E-11 0.0008 0.001 4.45E-01 
ECLIPSE White 0.0962 0.0273 4.30E-04 0.0112 0.0047 1.82E-02 
COPDGene AA 0.0595 0.0174 6.47E-04 0.0001 0.0016 9.69E-01 
ALD 
Meta-Analysis of Europeans -0.16 0.0241 3.14E-11 -0.0055 0.0027 4.16E-02 
COPDGene NHW -0.159 0.028 1.45E-08 -0.0054 0.0029 6.16E-02 
ECLIPSE White -0.1629 0.0474 6.09E-04 -0.0067 0.0081 4.10E-01 
COPDGene AA -0.0956 0.0556 8.58E-02 0.0046 0.006 4.44E-01 
Outcome untransformed; %LAA-950=percentage of low-attenuation area less than -950 Hounsfield units; ALD=Adjusted lung density; NHW=Non-Hispanic Whites; ECLIPSE= 





Supplementary Figure 1.1. Manhattan plots and quantile-quantile (Q-Q) plots of 
association results for annual change in emphysema 







%LAA-950=percentage of low-attenuation area less than -950 Hounsfield units; ALD=Adjusted lung density  
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%LAA-950=percentage of low-attenuation area less than -950 Hounsfield units; ALD=Adjusted lung density
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Risk for Chronic Obstructive Pulmonary Disease (COPD) is determined by both cigarette 
smoking and genetic susceptibility. The adverse effects of smoking on risk of COPD may differ 
by an individual’s genetic susceptibility, which raises the potential gene-by-smoking interactions. 
However, little is known about gene-by-smoking interactions on COPD risk.   
 
It has been reported that SERPINA1 variants, PI*Z allele and rs800738, interact with cigarette 
smoking on spirometric measure of lung function 1,2 and COPD risk 3, respectively.  For COPD-
related traits, genome-wide gene-by-smoking interaction studies have focused on quantitative 
measures of lung function 4,5.  While spirometric measures of lung function are used to diagnose 
COPD, no genome-wide studies have investigated gene-by-smoking interaction on risk of 
COPD itself. 
 
A recent large-scale genome-wide association study (GWAS) identified 82 distinct loci 
associated with risk of COPD 6. However, these identified variants explained less than 10% of 
the phenotypic variability on the liability scale. To fill the gap of the genetics of COPD explained 
by common variants, more of the phenotypic variability might be explained by including gene-
by-smoking interactions in GWAS model.   
 
A major challenge of studying gene-by-environment interactions is the much larger sample size 
required compared to conventional GWAS to detect marginal effects of genes 7. The 2-degree-
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of-freedom (2df) joint test leverages genetic main effects and gene-by-environment interaction 
effects simultaneously and can provide better power than the standard interaction test, 1-
degree-of-freedom (1df) test 8. Using a 2df test, recent large-scale genome-wide gene-by-
environment interaction studies of complex traits have identified new genetic factors as well as 
gene-by-environment interactions 4,9–13.  The availability of the large-scale UK Biobank (UKB) 
study, collecting a wide range of phenotypes as well as genetic data, could provide a promising 
opportunity to detect gene-by-environment interactions. 
 
Here, we performed genome-wide gene-by-smoking interaction analyses of COPD in the UKB 
study to identify novel genetic variants for risk of COPD while accounting for potential smoking 
interactions and assessed the impact of gene-by-smoking interactions on risk of COPD at 




Study populations  
The UKB is a population-based cohort of volunteers where over 500,000 individuals were 
originally recruited 14. We used UKB subjects as our discovery set. We also used two additional 
datasets, the COPDGene Study and the SpiroMeta Consortium, to further investigate significant 
results from UKB. COPDGene recruited former and current smokers whose smoking history is 
at least 10 pack-years 15. SpiroMeta is comprised of a total of 79,055 individuals from 22 studies 
16. All participants provided written informed consent and studies were approved by local 




Spirometric measures and genetic data 
Details of quality controls (QC) of spirometric measures, genetic markers and subjects in the 
UKB study are previously described 6,14,16. Briefly, to determine lung function, measures of 
forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) were derived from 
the spirometry volume-time series data, subjected to additional quality control based on 
ATS/ERS criteria 16,17. Genotyping was performed using Axiom UK BiLEVE array and Axiom 
Biobank array (Affymetrix, Santa Clara, California, USA) and imputed to the Haplotype 
Reference Consortium version 1.1 panel. We included independent subjects of European 
ancestry based on a combination of self-reported ethnicity data and principal components (PCs) 
data provided by UKB.  
 
Measures of smoking exposure 
We assigned smoking status to individuals in UKB based on their responses on questionnaires. 
Never-smokers included non-current-smokers or those who smoked less than 100 cigarettes in 
their life. Ever-smokers were defined as either current, most days (current or all days in the 
past) or smoked occasionally.  
 
For genome-wide gene-by-smoking interaction testing, we considered 2 binary smoking 
variables: Ever/Never and Current/Non-current smoker. For Ever/Never smokers, former- and 
current-smokers were included into the ever-smoker group. For Current/Non-current smokers, 
former- and never- smokers were included into the non-current-smoker group. Smoking 
variables were coded as 0 and 1 for the unexposed and exposed groups, respectively. Here, we 
refer Ever/Never-smoker analysis as “GxEver-smoking analysis” and Current/Non-current 





We defined COPD cases based on pre-bronchodilator spirometry according to modified Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) criteria for moderate airflow limitation: 
FEV1 less than 80% of predicted value (using reference equations from 18), and the ratio of 
FEV1/FVC less than 0.7.  
 
Genetic analysis 
We included markers with minor allele frequency (MAF) ≥ 0.01 and imputation quality score (r2) 
≥ 0.5. We performed a logistic regression analysis considering both genetic main effect and 
gene-by-smoking interaction effect (2df joint test) in the genome-wide analysis, adjusting for 
age, sex, genotyping array and the first 10 PCs. We used a 2df test to jointly assess both 
genetic main effect and interaction effect to search for new genetic variant of COPD and a 1df 
SNP-by-smoking interaction test to assess the interaction effects alone. Additionally, marginal 
GWAS were run stratified by each smoking variable. All genome-wide analyses were performed 
using Plink software (version 2.0, www.cog-genomics.org/plink/2.0).   
 
Conditional analysis 
We defined distinct ‘loci’ using a 1-Mb window (+/- 500kb) around the most significant SNP 
(lead variant). As our joint analysis was likely to include substantial overlap with previously 
described association studies of main effects for COPD, we performed conditional analysis of 
lead variants to determine whether our signals were independent of known loci for COPD 6 or 
lung function 16. As the current GCTA (http://cnsgenomics.com/software/gcta) tool does not 
account for gene-by-environment interactions in their conditional analysis, we took a stratified 
approach. We stratified by smoking exposed- and unexposed- groups and conditioned on 
recognized SNPs from previous GWASs of COPD 6 or lung function 16 within 2-Mb of the lead 
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variants. The conditioned 2df test for genetic main effects and interaction effects was then 
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, calculated from the genome-wide results. The Z statistics approximately follows a 
















which approximately follows a 2df chi-squared distribution under 𝐻0: 𝛽𝐺 = 𝛽𝐺𝐸 = 0 when the two 
strata are independent.  
 
Dose response analysis 
To further characterize significant results, we conducted a dose response analysis in all 
subjects and ever smokers (a secondary analysis). We tested gene-by-smoking dose interaction 
using the standard 1df test. We considered three quantitative measures of smoking dose: 
smoking duration, pack-years (PY) and cigarettes per day (CPD). We considered both a 
quantitative variable and a categorical variable grouped based on quartiles.  
 
Replication 
As the COPDGene cohort is enriched for heavy smokers, we hypothesized SNPs presenting a 
stronger association among the exposed group in UKB would also show some marginal 
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associations with risk of COPD in COPDGene subjects. With the selected SNPs, we tested for a 
marginal association between SNP and risk of COPD, adjusting for age, sex, smoking status, 
pack-years and genetic ancestry PCs in 5,342 Non-Hispanic White (NHW) subjects from 
COPDGene. With the selected SNPs, we further tested gene-by-smoking dose interaction 
based on the 1df test. As the Fagerstrom Test for Nicotine Dependence (FTND) measure was 
collected for current smokers in COPDGene, we additionally tested gene-by-FTND interaction. 
We considered both a quantitative variable of FTND score and a categorical variable grouped 
into mild (0-3), moderate (4-6) and severe (7-10) 20. 
 
We also attempted to replicate our results by lookup in a GWAS analysis of spirometric 
measures of lung function (FEV1, FVC and FEV1/FVC) stratified by ever- and never-smoker 
groups in SpiroMeta. Using summary statistics of these stratified results, we derived statistics of 
a 1df interaction test and a 2df joint test based on the same approach used for the stratified 
conditional analysis 10,19. The analysis in SpiroMeta has been previously published 16. Briefly, 
each study was performed as a linear regression adjusting for age, age2, sex, and height, by 
using rank-based inverse normal transformation, adjusting for population substructure by 
including genetic ancestry PCs or as linear mixed models, and performing separate analyses for 
ever- and never-smokers or using a covariate for smoking (for studies of related subjects). 





We analyzed 200,766 subjects including 179,689 controls and 21,077 COPD cases in the UKB 
study (Table 2.1). UKB subjects included 71,591 ever- (current- and former-smokers combined) 
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and 129,175 never-smokers; and 14,590 current- and 186,176 non-current-smokers (never- and 
former-smokers combined). COPDGene subjects included NHW 3,361 former-smokers and 
1,981 current-smokers. While UKB subjects had a higher proportion of COPD cases among 
current-smokers (31.5%) than former- (13.8%) and never-smokers (6.7%), COPDGene subjects 
(who were enriched for moderate-to-severe COPD) showed a higher proportion of COPD cases 
among former-smokers (54.5%) than current-smokers (49.4%).  
 
Genome-wide Results 
The analysis workflow is depicted in Figure 2.1. 
 
2df joint test. We identified 48 loci for GxEver- and 55 loci for GxCurrent- smoking analysis 
(defined using 1-Mb windows) at genome-wide significance (P<5.00E-08) (Supplemental 
Figure 2.1). The lead variants of 15 loci for GxEver- and 19 loci for GxCurrent- smoking 
analysis were previously reported variants in GWAS of COPD or lung function 6,16. For the 
remaining loci, we conducted a conditional analysis to search for new signal (see Method). 
After adjusting for reported variants, 2 loci, 16q22.1 - SMPD3 (lead variant: rs141322661, P2df 
=3.92E-09 from GxEver- and P2df =1.45E-08 from GxCurrent- smoking analysis) and 19q13.2 - 
EGLN2 (lead variant: rs2604894, P2df =5.87E-09 from GxCurrent smoking analysis), maintained 
genome-wide significance (Table 2.2 and Figure 2.2).  
 
In previous UKB GWAS of COPD examining only marginal effects 6, rs141322661 at 16q22.1 
reached genome-wide significance (P=1.88E-09), but not in overall meta-analysis of UKB and 
International COPD Genetics Consortium (ICGC) (P=1.90E-08) and rs2604894 at 19q13.2 did 
not reach genome-wide significance (P=1.17E-04). In our current/non-current stratified GWAS, 
rs2604894 showed a stronger association among current-smokers (OR (95% CI)=0.86 (0.82-
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0.91), P=2.52E-07) compared to among non-current-smokers (OR (95% CI)=0.96 (0.94-0.99), 
P=2.77E-03). Other signals were attenuated and did not reach our significance level, indicating 
that those findings are not novel.  
 
1df interaction test. We identified one locus - 15q25.1 (defined using 1-Mb windows) at genome-
wide significance (P <5.00E-08) for both GxEver- and GxCurrent-smoking analyses (Table 2.2, 
Figure 2.3 and Supplemental Figure 2.2). In the GxEver-smoking analysis, the lead variant, 
rs12440014 in CHRNB4, showed P1df interaction=8.96E-12, presenting significant association in 
ever-smokers (OR (95% CI)=0.85 (0.82-0.88), P=3.39E-19), but not in never-smokers.  
 
Interaction of reported variants  
We examined possible gene-by-smoking interactions on risk of COPD at 82 known COPD-
associated loci, 279 known lung function-associated loci and 2 loci previously reporting smoking 
interactions on lung function or COPD. Because results from the 2df test for these known loci 
predominantly showed genetic main effects, we evaluated results from the 1df test for gene-by-
smoking interactions at Bonferroni corrected significance.  
 
At known loci of COPD, rs55676755 in CHRNA3 and rs28534575 in CHRNB4, significantly 
interacted with smoking, presenting significant associations in ever-smokers (rs55676755: OR 
(95% CI)=1.19 (1.15-1.22), P=8.74E-28 and rs28534575: OR (95% CI)=0.85 (0.82-0.88), 
P=2.53E-18), but not in never-smokers. rs7642001 at 3q26.2 – MECOM showed a significant 
current smoking (P1df interaction=3.65E-04) but not ever smoking (P1df interaction=3.11E-01) interaction. 
At known loci for lung function, there was no statistically significant interactions with smoking. At 
loci previously reporting smoking interactions, PI*Z allele (rs28929474) - SERPINA1 significantly 
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interacted with both ever smoking (P1df interaction=6.70E-04) and current smoking (P1df 
interaction=7.19E-03).  
 
Selected SNPs  
To further investigate significant results, we selected 5 SNPs at 5 loci (Table 2.3 and Figure 
2.4). In the 2df joint test, rs141322661 at 16q22.1 – SMPD3 and rs2604894 at 19q13.2 - EGLN2 
reached genome-wide significance, independent of previously described loci of COPD and lung 
function. In the 1df interaction test, we included rs12440014 at 15q25.1 – CHRNB4. In 
previously reported variants, we selected rs7642001 at 3q26.2 – MECOM and rs28929474 - 
SERPINA1, with evidence of interaction.  
 
To examine whether selected SNPs are associated with smoking behavior, we checked regions 
of selected SNPs in the most recent and largest GWAS of smoking itself 21 (Supplemental 
Table 2.1). 15q25.1 and 19q13.2, were reported to be associated with CPD and current 
smoking.  
 
To further characterize the interactions, we conducted a dose response analysis 
(Supplemental Table 2.2). We considered smoking duration as a primary measure of smoking 
dose based on previous reports that smoking duration alone provides larger estimated effects 
on risk of COPD than PY 22. rs7642001 at 3q26.2 – MECOM, rs28929474 of SERPINA1, 
rs12440014 at 15q25.1 – CHRNB4 and rs2604894 at 19q13.2 – EGLN2 exhibited statistically 
significant interactions with smoking duration on COPD risk (P<0.05). In a dose response 
analysis within ever-smokers, significances of dose response were attenuated but rs7642001 





To replicate our findings, we used COPDGene and SpiroMeta (Table 2.3).  
 
COPDGene. As COPDGene is enriched for heavy smokers, we hypothesized SNPs showing a 
stronger association among the exposed group in the UKB should have some marginal 
associations with COPD risk in COPDGene. rs7642001 at 3q26.2 -MECOM, rs28929474 - 
SERPINA1, rs12440014 at 15q25.1 - CHRNB4 and rs2604894 at 19q13.2 - EGLN2 were 
nominally significantly associated with risk of COPD (P<0.05). In a dose response analysis, a 
stronger association between rs7642001 at 3q26.2 – MECOM and COPD was observed with 
longer duration of smoking (Pinteraction=6.20E-04) (Supplemental Table 2.3). For 1,937 current 
smokers in COPDGene available for FTND score, rs12440014 at 15q25.1 - CHRNB4 interacted 
with higher nicotine dependence (Pinteraction=4.37E-02).  
 
SpiroMeta. We replicated a significant interaction of rs12440014 at 15q25.1 – CHRNB4 with 
ever smoking on FEV1 (Pinteraction<0.05), presenting stronger association among ever-smokers 
compared to never-smokers in SpiroMeta (Table 2.3). We observed a significant interaction for 
rs7642001 at 3q26.2 - MECOM on FEV1 (P=1.97E-03). However, the direction of interaction 
effects was opposite between UKB and SpiroMeta. Allele “A” of rs7642001 was more 
significantly associated with decreased FEV1 among never-smokers (Beta (95% CI)=-0.04 (-
0.05, -0.02), P=3.31E-05) compared to ever-smokers (Beta (95% CI)=-0.01 (-0.03, 0.005), 
P=1.93E-01), while in UKB more significantly associated with increased risk of COPD among 
current-smokers (OR (95% CI)=1.20 (1.13-1.27), P=4.54E-10) compared to non-current-
smokers (OR (95% CI)=1.07 (1.04-1.09), P=3.09E-07). The stratified analysis for other 






We conducted a genome-wide gene-by-smoking interaction study of COPD risk, using a 2df 
joint test for genetic main effects and gene-by-smoking interaction effects on COPD risk. Most 
of the significant signals from 2df test had been reported in previous GWASs of COPD. 
However, we identified two loci, 16q22.1 – SMPD3 and 19q13.2 – EGLN2, reaching genome-
wide significance. We detected a genome-wide significant interaction with smoking at the 
15q25.1 locus – CHRNB4, previously identified in studies of COPD and smoking behavior. We 
confirmed SERPINA1 PI*Z-by-smoking interaction on COPD.  
 
The 16q22.1 region (lead variant: rs141322661) had reached genome-wide significance in 
previous GWAS of COPD in UKB subjects but not in overall meta-analysis.  rs141322661, an 
intron variant of SMPD3, is a low frequent variant in European populations (Allele frequency (G) 
=0.01 - 0.02), which may make it difficult to replicate this signal. Further investigation of 16q22.1 
region is required.  
 
The 19q13.2 region (lead variant: rs2604894) could only be observed through genome-wide 
association analysis accounting for current-smoking interaction in UKB subjects. In the previous 
UKB GWAS of COPD not incorporating interaction in the model, rs2604894 did not reach  
genome-wide significance 6. In conventional GWAS of COPD using cohorts enriched for 
smokers, rs2604894 was reported to be significantly associated with COPD risk (OR (95% 
CI)=0.74 (0.65-0.84), P=3.41E-08) 23. This study included cohorts such as COPDGene 15 and 
ECLIPSE 24 designed to identify genetic factors for COPD, recruiting former- and current-
smokers. Such different study design between the UKB study, a population-based cohort, and 
COPD-related cohorts may have attenuated the statistical significance of rs2604894 association 
and hindered the replication in previous marginal GWAS in the UKB. Our finding highlights the 
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importance of accounting for heterogeneity in genetic effect across exposure group in 
association discovery studies.  
 
The 19q13.2 region contains several genes related to smoking behavior. rs2604894 is an intron 
variant of EGLN2. CYP2A6 adjacent to EGLN2 is involved in nicotine metabolism 25. A previous 
study reported that EGLN2 variants were not associated with nicotine metabolism but with CPD 
independent of CYP2A6 variants 26. Significant lung expression quantitative traits loci (eQTLs) 
were detected with EGLN2 27. EGLN2 is known to be involved in regulating hypoxia tolerance 
and apoptosis in cardiac and skeletal muscle. Further functional studies on 19q13.2 region are 
clearly warranted to verify the contribution of susceptibility genes in COPD.  
 
We identified genome-wide significant smoking interaction effects at 15q25.1 in UKB and 
replicated in SpiroMeta, presenting associations primarily in ever-smokers. The CHRNA5/A3/B4 
gene cluster on 15q25.1 encodes the nicotinic acetylcholine receptor subunits α5, α3 and β4. 
Variants in this gene cluster have been robustly associated with several lung-related traits, such 
as lung cancer 28 and COPD 6 as well as smoking-related phenotypes, such as smoking quantity 
21,29–31 and nicotine dependence 29. Because smoking is the most important environmental risk 
factor for COPD, it is quite likely that the association of variants in 15q25.1 region with COPD 
mediates through smoking behavior 32.     
 
We noted a significant dose response of rs12440014 at 15q25.1 in UKB but not in COPDGene. 
It may be simply due to a smaller sample size in COPDGene. However, given that COPDGene 
is enriched for heavy smokers and thus COPD cases compared to UKB, a population-based 
cohort, our results may suggest other possibilities; 1) the genetic susceptibility of 15q25.1 region 
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to COPD would be substantial at relatively low level of smoking exposure and/or 2) COPD 
patients are likely to quit smoking, diluting the association between 15q25.1 and COPD.   
 
We confirmed a known interaction on COPD, SERPINA1 (PI*Z allele)-by-smoking interaction in 
our study population 1,2. In previous study, a PI*Z-by-smoking interaction was identified on FEV1 
(P=0.03) and COPD status (P=0.01) in subjects of European ancestry 2. The SERPINA1, 
encoding the AAT protein, influences the risk to COPD 33. The homozygosity for PI*Z allele is 
the most common cause of AAT deficiency. It follows a Mendelian pattern of inheritance, but 
there is marked variability in the development and severity of COPD in PI*ZZ individuals. Our 
replication can help to understand variable manifestations of COPD among individuals with AAT 
deficiency.  
 
There are several limitations in our study. First, power for detecting interactions and discovering 
novel genetic risk factors may be limited even in this large sample size 34. Second, we only 
included independent subjects of European ancestry. Investigation of more ethnically diverse 
populations should lead to more robust inferences of gene-by-environment interaction by 
increasing diversity of not only environmental exposure but also genetic exposure 35. Third, our 
use of two smoking measures, ever smoking and current smoking, in genome-wide investigation 
may have limited the interpretation of our results. Smokers with more severe COPD are more 
likely to reduce or quit smoking and those without symptoms are more likely to continue 
smoking and thus be current smokers, described as “healthy smoker effect”. Such phenomenon 
is highly possible in COPDGene and may also be relevant for UKB as well 36 . Fourth, we used 
self-reported smoking history. Measurement errors of smoking may lead to our lack of findings 
of interaction 7. Fifth, a “healthy volunteer” selection bias exists in UKB study. The UKB cohort is 
not representative of the general population; UKB participants are less likely to smoke and have 
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fewer self-reported health conditions compared with the general population 37. However, 
generalizability is not necessary to make an inference of associations. Its large sample size and 
heterogeneity of smoking exposures would still make our findings valid.  
 
Despite our large sample size (n=200,766), we detected only one locus reaching conventional 
genome-wide significance for the 1df test for gene-by-smoking interaction. To understand gene-
by-smoking interaction on COPD risk or more broadly, gene-by-environment interaction, other 
approaches should also be considered. First, integration of genetic markers and other “-omics” 
data (transcriptomic, proteomic or epigenomic data) would be helpful. For example, genetic 
markers influencing other biomarkers such as eQTL may be more likely to interact with smoking 
38. Second, rare variants could also play a significant role on gene-by-environment interaction. 
Third, to define the sub-population at highest risk of COPD, a polygenic risk score (PRS) 
approach might be better useful than a genome-wide approach using a single variant with 
relatively small effect size 39.  
 
In summary, a genome-wide investigation incorporating gene-by-smoking interaction identified 
two COPD loci, 16q22.1 – SMPD3 and 19q13.2 – EGLN2. We observed the 19q13.2 region in 
our joint test which did not reach genome-wide significance in previous marginal GWAS in UKB, 
suggesting the importance of accounting for heterogeneity in genetic effect across exposure 
group in association discovery studies. We detected a genome-wide significant interaction at the 
15q25.1 region primarily having an association among ever-smokers. We replicated one known 
interaction, PI*Z allele-by-smoking interaction on COPD. Cigarette smoking is the most 
important environmental risk factor for COPD, but individuals vary in their susceptibility to the 
effects of cigarette smoke. It raises the possibility of detectable gene-by-smoking interactions, 
but we identified few significant interactions in our large-scale study. Considering diverse 
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populations and other approaches such as integration of genetic data and other “-omics” data 
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Table 2.1. Subject characteristics stratified by smoking status 
  
 UK Biobank COPDGene 
 Never Former Current Former Current 
N 129175 57001 14590 3361 1981 
Moderate COPD 8631 ( 6.7) 7857 (13.8) 4589 (31.5) 1831 (54.5) 978 (49.4) 
Age 55.55 (8.05) 57.91 (7.64) 54.12 (8.06) 64.95 (8.23) 57.48 (7.80) 
Female 50194 (38.9) 29175 (51.2) 6941 (47.6) 1620 (48.2) 907 (45.8) 





















FEV1/FVC 0.77 (0.06) 0.76 (0.07) 0.72 (0.09) 0.61 (0.19) 0.65 (0.16) 
      
Mean (SD) for continuous variable; N (%) for categorical variable; FEV1=Forced expiratory 




Table 2.2 Significant results of 2df join test and 1df interaction test in UK Biobank 
 
 









OR (95% CI) P OR (95% CI) P P 
Significant from 2df joint test* 
rs14132266
1 
16:68398875 SMPD3 G/A 0.01 
Ever 
Smoking 
0.76 (0.65-0.88) 2.09E-04 0.94 (0.78-1.15) 5.72E-01 3.92E-09 
rs14132266
1 
16:68398875 SMPD3 G/A 0.01 
Current 
Smoking 
0.77 (0.69-0.86) 1.47E-06 0.81 (0.62-1.07) 1.45E-01 1.45E-08 
rs2604894 19:41292404 EGLN2 A/G 0.45 
Current 
Smoking 
0.96 (0.94-0.98) 1.28E-03 0.9 (0.84-0.95) 4.11E-04 5.87E-09 
Significant from 1df interaction test* 
rs7170068 15:78912943 CHRNA3 A/G 0.22 
Current 
Smoking 
0.96 (0.93-0.98) 2.38E-03 0.79 (0.74-0.86) 1.82E-09 6.08E-16 
rs12440014 15:78926726 CHRNB4 G/C 0.24 
Ever 
Smoking 
1.02 (0.98-1.06) 3.14E-01 0.83 (0.79-0.88) 8.96E-12 6.96E-18 
Significant from 1df interaction test in candidate variants** 
rs7642001 3:168746145 MECOM A/G 0.37 
Current 
Smoking 
1.07 (1.04-1.09) 3.20E-07 1.12 (1.05-1.19) 3.65E-04 1.73E-14 
rs28929474 14:94844947 SERPINA1 T/C 0.02 
Ever 
Smoking 
0.95 (0.85-1.07) 4.02E-01 1.3 (1.12-1.52) 6.70E-04 1.10E-04 
 
          
EAF: Effect Allele Frequency; Interaction: Interaction test with 1 degree of freedom; 2DF Joint: Joint test with 2 degrees of freedom of genetic main and 
interaction effects; *Genome-wide statistical significance (P<5.00E-08) applied; **Bonferroni corrected statistical significance (P<1.00E-04) applied. 
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Table 2.3. Replications of selected SNPs in COPDGene and SpiroMeta 
  
 
COPDGene NHW SpiroMeta (FEV1) 






























0.01 (-0.05, 0.08) 
6.45E-
01 



































































0.01 (-0.01, 0.03) 
4.95E-
01 




             
EAF: Effect Allele Frequency; Interaction: Interaction test with 1 degree of freedom; 2DF Joint: Joint test with 2 degrees of freedom of genetic main and interaction effects; Marginal association between 
each selected SNP and COPD was tested in COPDGene; Lookup of selected SNPs in GWAS of spirometric measures of lung function stratified by never- and ever-smoker groups in SpiroMeta; EAFs 
from COPDGene and SpiroMeta were similar. 
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Figure 2.2. Regional plots of 16q22.1 and 19q13.2 region based on 2df joint test 
Figure 2.2a. 16q22.1 region 
 




Figure 2.3. Manhattan plot and regional plot of 15q25 region based on 1df interaction test 
Figure 2.3a. Manhattan plot of 15q25 region 
 









Supplemental Table 2.1. Lookup in GWAS of Smoking (Liu et al., 2019)  
 
Trait Variant Chromosome Position 
Effect 
Allele EAF Beta P 
cigarettes per day rs12438181 15 78812098 A 0.22 -0.01853 4.97E-10 
cigarettes per day rs10519203 15 78814046 A 0.66 -0.09362 3.12E-286 
cigarettes per day rs28438420 15 78836288 T 0.55 0.01756 1.25E-12 
cigarettes per day rs72740955 15 78849779 T 0.34 0.03175 2.42E-34 
cigarettes per day rs146009840 15 78906177 T 0.34 0.02212 2.00E-17 
cigarettes per day rs28681284 15 78908565 T 0.21 -0.04868 2.10E-58 
cigarettes per day rs8040868 15 78911181 C 0.4 0.01601 1.79E-10 
cigarettes per day rs3743063 15 79065171 C 0.56 -0.01672 1.53E-11 
cigarettes per day rs143200968 19 41338847 C 0.03 -0.0861 6.97E-28 
cigarettes per day rs56113850 19 41353107 C 0.56 0.05231 4.01E-99 
cigarettes per day rs8192726 19 41354496 A 0.07 -0.03934 8.35E-16 
cigarettes per day rs117824460 19 41371480 G 0.03 -0.09526 7.66E-35 
current vs. former rs518425 15 78883813 G 0.28 -0.0305 1.72E-12 
current vs. former rs145580088 19 41342842 G 0.02 0.09096 9.48E-13 
current vs. former rs59586387 19 41375030 G 0.07 0.05139 3.37E-11 
        
EAF: Effect Allele Frequency       
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Supplemental Table 2.2. Interactions of selected SNPs with smoking dose measures in UK Biobank and COPDGene 
  
 
UK Biobank (n=200,766) UK Biobank ever smokers (n=67,761) COPDGene smokers (n=5,342) 
 











Allele OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P 


















































































































































































































































































































































































































































MECOM A G   
  
  
   














T C   
  
  
   












CHRNB4 C G   
  
  
   












SMPD3 A G   
  
  
   












EGLN2 G A   
  
  
   








                  
Smoking Duration, Pack-years and Cigarette per day were categorized into quartiles (Q1, Q2, Q3 and Q4).; FTND score was categorized into mild (0-3), moderate (4-6) or severe (7-10).; *Set the allele increasing the risk; **Never smoker group was set as a reference group; ***The 
lowest group of smoking dose (Q1) was set as a reference group; Ref. Allele: Reference Allele; 1937 COPDGene subjects were included for FTND score analysis. 
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Supplemental Table 2.3. Stratified analysis by ever smoking for selected SNPs in SpiroMeta (FVC and FEV1/FVC)  








Beta (95% CI) P Beta (95% CI) P P P 
FVC 











rs11735046 4:145008115 A/G 0.0079 (-0.0188, 0.0346) 
5.61E-
01 






rs56326741 6:32067967 T/C 0.0145 (-0.0128, 0.0418) 
2.99E-
01 
















rs28534575 15:78923845 G/T 0.0061 (-0.0134, 0.0257) 
5.38E-
01 






rs2604894 19:41292404 A/G -0.002 (-0.018, 0.014) 
8.03E-
01 







rs7642001 3:168746145 A/G -0.0177 (-0.0344, -0.001) 
3.74E-
02 






rs11735046 4:145008115 A/G -0.0258 (-0.0525, 9e-04) 
5.82E-
02 






rs56326741 6:32067967 T/C 0.0182 (-0.0091, 0.0455) 
1.92E-
01 
















rs28534575 15:78923845 G/T 0.0066 (-0.013, 0.0261) 
5.10E-
01 






rs2604894 19:41292404 A/G 0.0106 (-0.0054, 0.0267) 
1.93E-
01 






         
Ref. Allele: Reference Allele        
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Supplemental Figure 2.1. Manhattan plot and QQ plot of 2df joint test 
Supplemental Figure 2.1a. Gene-by-ever smoking interaction analysis 
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Supplementary Figure 2.2. Manhattan plot and QQ plot of 1df interaction test 








Chapter 4. Gene-by-smoking interaction study on chronic obstructive pulmonary disease 
using a polygenic risk score of lung function
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Chapter 4. Gene-by-smoking interaction study on chronic obstructive pulmonary disease 




Complex diseases are influenced by the interplay between environmental and genetic factors. 
Gene-by-environment interaction is an important component to understand disease mechanism. 
Statistical interaction can be assessed on multiplicative or additive scales. Additive interactions 
are less explored than multiplicative interactions in gene-by-environment interaction studies, but 
such interaction holds greater public health relevance. Additive interaction can be useful when 
targeting sub-populations where the intervention will be most effective, particularly when 
resources are constrained 1.  
 
A relatively small effect of a single genetic marker such as single-nucleotide polymorphism 
(SNP) on an outcome makes it challenging to detect and replicate gene-by-environment 
interactions. Several studies have attempted to utilize a polygenic risk score (PRS) aggregating 
genetic variants into a single measure to explore gene-by-environment interactions 2–6. The PRS 
is the sum of the number of risk alleles for each SNP identified from genome-wide association 
study (GWAS). To define the sub-populations more susceptible to a complex disease, this PRS 
could be a better measure to study gene-by-environment interactions than any single marker.  
 
Risk of Chronic Obstructive Pulmonary Disease (COPD) is influenced by cigarette smoking and 
genetic susceptibility. The single most important environmental risk factor for COPD is cigarette 
smoking, but smoking effects vary among individuals possibly due to their genetic makeup. It 
raises the potential of gene-by-smoking interactions. However, to date little is known about 
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gene-by-smoking interaction on COPD. A recent study of genome-wide gene-by-smoking 
interaction on risk to COPD reported evidence of interaction with two genetic regions known to 
influence risk to COPD, CHRNB4 and SERPINA1 in European populations 7. Other known 
COPD or lung function risk loci did not seem to interact with smoking on COPD risk.  
 
Aschard et al. 2017 tested for interaction between a PRS of 26 SNPs in relation to forced 
expiratory volume in 1 second (FEV1) or the ratio of FEV1/ forced vital capacity (FVC) identified 
from a GWAS of lung function 8 and smoking exposure on lung function 5. A recent large-scale 
GWAS identified 279 distinct loci associated with lung function and tested for interaction 
between a PRS based on these 279 lung function SNPs and ever-smoking on quantitative 
measures of lung function (FEV1/FVC) and risk to COPD 9.  
 
Expanding previous studies of PRS-by-smoking interaction on lung function and/or COPD, our 
study tests for potential interactions between a lung function PRS and smoking on risk to COPD 
under multiplicative and additive models in a large cohort of subjects from the UK Biobank 
study. Our aim is to examine whether effects of smoking on COPD risk are modified by a lung 
function PRS. We hypothesize that the increased risk of COPD by smoking would be greater 




Study population  
We used data from the UK Biobank (UKB) study, a population-based cohort of volunteers where 
over 500,000 individuals were originally recruited 10. Details of quality controls (QC) of 
spirometric measures, genetic markers and subjects in the UKB study are previously described 
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9–11. Briefly, to determine lung function, measures of FEV1 and FVC were derived from the 
spirometry volume-time series data, subjected to additional quality control based on ATS/ERS 
criteria 9,12. Genotyping was performed using Axiom UK BiLEVE array and Axiom Biobank array 
(Affymetrix, Santa Clara, California, USA) and imputed to the Haplotype Reference Consortium 
(version 1.1) panel. We included independent subjects of European ancestry based on the 




We assigned smoking status to individuals in UKB based on their responses on questionnaires. 
Never-smokers included non-current-smokers or those who smoked less than 100 cigarettes in 
their life. Ever-smokers were defined as either current, most days (current or all days in the 
past) or smoked occasionally. We defined pack-years as packs of cigarettes smoked per day 
multiplied by years smoked. Pack-years was 0 for never-smokers. For ever-smokers, we set 
pack-years to cigarettes per day divided by 20 multiplied by duration of smoking according to 
individual’s smoking status (former or current). We considered never-/ever-smoking status as a 
binary variable and pack-years as both a quantitative variable and a categorical variable 
grouped based on ≤10, 10.1-20, 20.1-30, 30.1-40, 40.1-50 and >50 with pack-years, where the 
lowest exposure group (packyears ≤10) served as the reference group. As a secondary 
analysis, we considered never-/former-/current-smoking status and pack-years as a categorical 
variable with pack-years=0 (i.e. never-smoker) as the reference group.  
 
Polygenic risk score based on lung function  
Using the 279 SNPs previously associated with lung function in the UKB (where most 
individuals were identified as having European ancestry), we generated a PRS by summing the 
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number of risk alleles for each SNP weighted by their estimated effect size for FEV1/FVC, as 
previously described 9, in our study population. We divided individuals into deciles according to 
their value of the PRS. We analyzed PRS as both a quantitative variable and a categorical 
variable (10 decile groups). Subsequently, we will refer to this lung function PRS as simply PRS.  
 
Outcome 
We defined COPD cases based on pre-bronchodilator spirometry following the modified Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) criteria for moderate airflow limitation: 
FEV1 less than 80% of predicted value (using reference equations from 13), and the ratio of 
FEV1/FVC less than 0.7.  
 
Statistical analysis  
We performed a logistic regression analysis, adjusting for age, age2, sex, height, genotyping 
array and the first 10 PCs. We performed two stratified analyses: 1) by PRS group to estimate 
the odds ratio (OR) of being a COPD case and its 95% confidence interval (95% CI) for the 
smoking variable, which is relevant to our hypothesis that PRS might be an effect modifier of the 
association between cigarette smoking and risk to COPD, and 2) by smoking group to estimate 
OR and 95% CI for the PRS variable, which provides a different perspective that the association 
between PRS and COPD would differ by smoking behavior.  
 
Tests for interactions. To statistically test for PRS-by-smoking interaction, we included the 
interaction term (PRS*Smoking) in the model and assessed the multiplicative interaction 
(ORPRS*Smoking) based on maximum likelihood estimation. If the estimated ORPRS*Smoking>1, the 
model would indicate a super-multiplicative interaction, while the estimated ORPRS*Smoking<1, a 
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sub-multiplicative interaction. We tested the additive interaction calculating the Relative Excess 
Risk due to Interaction (RERI) with the following equations 1.  
𝑅𝐸𝑅𝐼𝑂𝑅 = 𝑂𝑅𝑃𝑅𝑆∗𝑆𝑚𝑜𝑘𝑖𝑛𝑔 − 𝑂𝑅𝑃𝑅𝑆 − 𝑂𝑅𝑆𝑚𝑜𝑘𝑖𝑛𝑔 + 1 
We assume the outcome is rare and thus ORs approximate risk ratios (RRs). When the 
RERI>0, the model would indicate a super-additive interaction, while the RERI<0, a sub-additive 
interaction. When putting into a public health context, RERI>0 implies the public health 
consequences of an intervention on smoking would be larger in individuals with a higher genetic 
risk compared to individuals with a lower genetic risk. The 95% CI of RERI was obtained using 
the delta method with “nlcom” command in STATA software (version 14.2 
https://www.stata.com/) 14. 
 
Joint effects of smoking and PRS. We also examined joint effect of smoking and PRS to assess 
deviation of the observed joint effect from the expected effect under a multiplicative or additive 
model as another way to test for statistical interaction. To avoid the high-dimensional issue that 
would result if all 10 deciles of PRS were modeled, we focused on the two extremes of low and 
high risk (i.e. 1st and 10th deciles) of PRS. We created a categorical variable with mutually 
exclusive strata formed by the cross classification of smoking and PRS (10th vs. 1st decile). In 
this analysis, the reference category becomes the group with lowest smoking exposure (never-
smoker or pack-years≤10) in the lowest PRS group. We then regressed COPD case on this 
categorical variable. The expected OR was calculated as the product of the observed main 
effects for smoking and PRS under the multiplicative model and as the sum of the main effects 
minus 1 under the additive model 15. If the estimated OR is greater than that expected under the 
multiplicative or additive model, respectively, it would indicate a super-multiplicative or super-
additive interaction. If the estimated OR is less, it would indicate a sub-multiplicative or sub-




Population attributable risk. The population attributable risk (PAR) can be interpreted as the 
proportion of COPD cases expected to occur in a population that is attributable to a particular 
exposure or combination of exposures. We estimated PARs for smoking, PRS and the 
combination of both factors. The combined PAR for smoking and PRS was computed from 
estimates of the main and joint ORs under a logistic regression model using the following 
equations.  




For j mutually exclusive strata formed by the cross classification of smoking and PRS, ρj is the 
proportion of all cases in stratum j and ORj is the OR in group j compared with the reference 
group 16. Analyses were performed using R software (version 3.6.0, https://www.r-project.org/) 





We used data on 200,766 subjects of European ancestry including 179,689 controls and 21,077 
COPD cases from the UKB study (Table 3.1). The overall prevalence of COPD was 10.5% in 
our study population. As expected, the proportion of ever-smokers among controls was lower 
(32.9%) than among cases (59.1%). The mean pack-years (Mean (SD)) was 6.09 (12.53) in 
controls and 19.71 (23.91) in COPD cases. The proportion of COPD cases was significantly 




Overall associations of smoking and lung function PRS with COPD 
The estimated OR (95% CI) for risk of COPD comparing ever-smokers to never-smokers was 
2.37 (2.30-2.44) (Table 3.2).  The estimated OR (95% CI) for COPD comparing smokers with 
very heavy exposure (i.e. pack-years>50) to the reference group of those with less than 10 
pack-years was 5.77 (5.27-6.31) among ever-smokers. When treated as a continuous variable, 
PRS was significantly associated with an increased risk of COPD (OR (95% CI)=1.04 (1.03-
1.04)). When PRS was categorized into deciles, the estimated ORs for COPD tended to 
increase across deciles of PRS; the estimated OR (95% CI) for COPD comparing the 2nd to 10th 
decile to the lowest group (i.e. 1st decile) was 1.38 (1.27-1.50), 1.52 (1.4-1.66), 1.73 (1.59-1.88), 
1.85 (1.71-2.01), 2.20 (2.03-2.38), 2.42 (2.23-2.61), 2.62 (2.42-2.84), 3.11 (2.88-3.36) and 4.35 
(4.03-4.68), respectively. Associations of other smoking measures (never/former/current-
smoking status and a categorical variable of pack-years with never-smoker as a reference) are 
provided in Supplemental Table 3.1.  
 
Interaction between ever-smoking and PRS 
The strength of association between ever-smoking and COPD was greater in the lower decile of 
PRS (Figure 3.1a). Viewed differently, the strength of association between each decile of PRS 
and risk of COPD was greater among never-smokers compared to ever-smokers across the 2nd 
to 10th deciles of PRS (Figure 3.1b).  
 
In Table 3.3, focusing on two extreme groups of PRS (i.e. 1st and 10th decile), the estimated OR 
(95% CI) for COPD comparing ever-smokers to never-smokers was greater in the lowest PRS 
group (2.81 (2.46-3.22)) than in the highest PRS group (2.19 (2.02-2.37)). We observed a 
statistically significant sub-multiplicative interaction (OR (95% CI)=0.79 (0.68-0.92), P=3.11E-
03) and super-additive interaction (RERI (95% CI)=4.35 (3.54-5.16), P=6.28E-26). The 
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estimated OR (95% CI) for joint effects of smoking and PRS was 11.26 (9.99-12.68). This 
observed OR was less than that expected OR (13.88) under the multiplicative model and 
greater than the expected OR (6.91) under the additive model visualized in Figure 3.2. The 
estimated PAR for ever-smoking was 34.1% and for PRS was 60.3%. The combined PAR for 
smoking and PRS was 76.5%. As a continuous variable of PRS, we also observed a statistically 
significant sub-multiplicative interaction (OR (95% CI)=0.9957 (0.993-0.9983), P=1.16E-03) and 
super-additive interaction (RERI (95% CI)=0.07 (0.05-0.09), P=6.35E-25) (data not shown).  
 
Interaction between pack-years and PRS in ever-smokers 
Because we observed a statistically significant interaction between ever-smoking and PRS, we 
then tested whether the increased risk of COPD by smoking dose measured by pack-years was 
modified by PRS within ever-smokers (Table 3.4). The strength of the association between 
pack-years and COPD tended to be greater in the lowest PRS group compared to the highest 
PRS group. We found no evidence of statistically significant interaction on multiplicative scale 
(P>0.05 for all categories of pack-years). The interaction on an additive scale was statistically 
significant for all categories of pack-years (RERI ranged from 1.45 to 13.50, P<2.00E-03). The 
log scale of ORs for joint effects of pack-years and PRS are depicted in Figure 3.3. Estimated 
ORs are provided in Supplemental Table 3.2. The ORs (95% CI) for COPD showed an 
increasing trend across strata for both categories of pack-years or PRS. The estimated OR 
(95% CI) for joint effects of pack-years>50 and PRS (i.e. OR comparing a group of pack-
years>50 in the highest PRS group to a reference group of pack-years≤10 in the lowest PRS 
group) was 22.11 (16.1-30.36). Of note, we observed similar ORs for COPD between groups 
with relatively high smoking exposure in the lowest PRS group and those with relatively low 
smoking exposure in the highest PRS group. For example, the OR (95% CI) for a group of pack-
years>50 in the lowest PRS group was 5.79 (4.19-8.00), while for a group of 10.1<pack-
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years<20 in the highest PRS group was 5.73 (4.40-7.46). Results of other smoking measures 
(never/former/current-smoking status and a categorical variable of pack-years with never-
smoker as the reference group) are provided in Supplemental Tables 3.3 and Supplemental 




We tested for possible gene-by-smoking interactions on COPD risk using a polygenic risk score 
(PRS) based on genetic markers achieving genome-wide significance as influencing 
quantitative measures lung function identified from GWAS in European population. Our study 
provides evidence for a sub-multiplicative interaction and super-additive interaction between 
smoking and PRS on the risk of COPD. Particularly, among ever-smokers, our analyses 
showed strong evidence for a super-additive interaction between smoking dose and PRS on risk 
of COPD. It indicates the expected number of cases that could be avoided by smoking 
prevention efforts is larger among subjects with higher genetic predisposition.  
 
We noted a sub-multiplicative interaction between ever-smoking and PRS. Our finding is 
consistent with a previous report that OR (95% CI) for an interaction between PRS based on the 
279 SNPs found to influence lung function and ever-smoking on risk of COPD was below one, 
0.96 (0.92-0.99) (P=1.50E-02) 9. This estimated OR suggests OR for ever-smoking is less 
among individuals with higher PRS (i.e. the increased risk of COPD as a result of smoking is 
smaller among individuals who are more genetically susceptible to COPD).  
 
Under the additive model, however, our results showed a strong super-additive interaction 
where the increased risk of COPD due to smoking was greater among individuals who are more 
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genetically susceptible to COPD, which is consistent with our prior hypothesis. To our 
knowledge, this is the first report of possible gene-by-smoking interactions on risk to COPD on 
an additive scale using a PRS measure. In the public health context, the predicted reduction in 
risk of COPD from smoking intervention would be larger in individuals with a higher genetic risk. 
These findings may appear somewhat contradictory, but they do provide evidence for the 
potential application of genetic information in targeted smoking intervention programs. However, 
ethical issues to use genetic information in public health settings should be carefully considered. 
 
Interestingly, we observed similar estimated ORs for COPD between groups of individuals with 
relatively high smoking exposure and low genetic predisposition and those of individuals with 
relatively low smoking exposure and high genetic predisposition among ever-smoker. Subjects 
in these groups were about 4-5.7 times more likely to develop COPD than subjects who had low 
smoking exposure and low genetic predisposition. This finding provides two important 
messages. First, among those who have a low genetic predisposition, there is still substantial 
risk of developing COPD due to smoking behavior. This highlights the importance of smoking 
cessation regardless of an individual’s genetic susceptibility in preventing COPD. Second, for 
those who have a high genetic predisposition, they could reduce their risk to develop COPD by 
changing their smoking behavior, comparable to those who have a low genetic predisposition.  
 
There are several limitations in our study. First, our estimated interaction measures can be 
inflated. We calculated RERI assuming the disease is rare in our population, but we observed a 
high proportion of COPD cases (>10%) in some strata of smoking and PRS. Second, our 
analysis was deliberately limited to two extreme groups of PRS when testing for interaction. We 
sought to minimize high-dimensional issue when considering 10 distinct decile groups of PRS. 
Considering middle groups of PRS (the vast majority of the UKB cohort) could provide a more 
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comprehensive picture of PRS-by-smoking interactions. Third, we did not calculate the absolute 
risk in this paper. We tested for additive PRS-by-smoking interaction but did not formally test for 
differences in actual absolute risk. Fourth, our study included only subjects of European 
ancestry. It is not clear whether these results can be generalized to other racial/ethnic groups. 
 
In conclusion, our study provides strong evidence for additive interaction between smoking and 
PRS on the risk of COPD for the first time. Under an additive model, these findings suggest 
efforts of smoking intervention to prevent COPD would be larger for individuals who are more 
genetically predisposed to this disease. 
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Table 3.1. Subject Characteristics 
  Control COPD Case Total 
N 179689 21077 200766 
Age (Mean (SD)) 55.73 (8.02) 59.36 (7.31) 56.11 (8.03) 
Female (%) 75348 (41.9) 10962 (52.0) 86310 (43.0) 
Smoking measures 
   
Ever smoker (%) 59145 (32.9) 12446 (59.1) 71591 (35.7) 
Former smoker (%) 49144 (27.3) 7857 (37.3) 57001 (28.4) 
Current smoker (%) 10001 ( 5.6) 4589 (21.8) 14590 ( 7.3) 
Pack-Years (Mean (SD)) 6.09 (12.53) 19.71 (23.91) 7.52 (14.77) 
Smoking duration (Mean (SD)) 6.95 (12.28) 19.38 (19.08) 8.25 (13.70) 
Cigarette per day (Mean (SD)) 5.42 (9.66) 11.73 (12.90) 6.08 (10.23) 
Polygenic risk score 
   
1st decile (%) 19033 (10.6) 1044 ( 5.0) 20077 (10.0) 
10th decile (%) 16332 ( 9.1) 3745 (17.8) 20077 (10.0) 
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Table 3.2. Overall associations of smoking and lung function PRS with COPD 
Exposure OR (95% CI) 
Ever smoking 
Never smoker 1.00 (Reference) 
Ever smoker 2.37 (2.3-2.44) 
Pack-Years 
Pack-Years 1.03 (1.03-1.03) 
Category of Pack-Years 
≤10 1.00 (Reference) 
10.1-20 1.55 (1.44-1.66) 
20.1-30 1.65 (1.53-1.79) 
30.1-40 2.99 (2.75-3.24) 
40.1-50 4.20 (3.83-4.59) 
>50 5.77 (5.27-6.31) 
Continuous PRS 
PRS 1.04 (1.03-1.04) 
Decile of PRS 
1 1.00 (Reference) 
2 1.38 (1.27-1.5) 
3 1.52 (1.4-1.66) 
4 1.73 (1.59-1.88) 
5 1.85 (1.71-2.01) 
6 2.20 (2.03-2.38) 
7 2.42 (2.23-2.61) 
8 2.62 (2.42-2.84) 
9 3.11 (2.88-3.36) 
10 4.35 (4.03-4.68) 
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Table 3.3. Interaction between ever-smoking and PRS on the risk of COPD 




% of COPD 
case 
OR (95% CI) n 
% of COPD 
case 
OR (95% CI) 
















OR (95% CI) for 
smoking within 
PRS group 
    
2.81 (2.46-
3.22) 
    2.19 (2.02-2.37)   
Measure of interaction on multiplicative scale: ratio of ORs (95% CI)=0.79 (0.68-0.92), P=3.11E-03 
 
Measure of interaction on additive scale: RERI (95% CI)=4.35 (3.54-5.16), P=6.23E-26 
  
Expected OR for smoking and PRS under multiplicative model=13.88 
   
Expected OR for smoking and PRS under additive model=6.91 
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Table 3.4. Interaction between pack-years and PRS on the risk of COPD in ever-smokers 
 Stratum-specific effects 
 Lowest PRS group Highest PRS group Interaction on multiplicative scale Interaction on additive scale 
Pack-years n % of COPD case OR (95% CI) n % of COPD case OR (95% CI) OR (95% CI) P RERI (95% CI) P 
≤10 1933 0.04 1.00 (Reference) 1769 0.13 1.00 (Reference)     
10.1-20 1886 0.05 1.30 (0.95-1.78) 1927 0.2 1.37 (1.15-1.65) 1.14 (0.8-1.64) 4.70E-01 1.45 (0.52-2.38) 2.00E-03 
20.1-30 1312 0.08 1.62 (1.16-2.24) 1281 0.31 1.55 (1.27-1.9) 1.22 (0.85-1.75) 2.87E-01 2.27 (1.04-3.51) 2.95E-04 
30.1-40 751 0.17 3.13 (2.25-4.35) 896 0.47 2.75 (2.22-3.4) 1.08 (0.75-1.56) 6.81E-01 6.05 (3.61-8.49) 1.17E-06 
40.1-50 408 0.27 5.58 (3.94-7.89) 472 0.56 3.96 (3.08-5.08) 0.85 (0.57-1.28) 4.34E-01 10.19 (5.43-14.96) 2.79E-05 
>50 458 0.32 6.66 (4.75-9.33) 471 0.65 5.11 (3.94-6.61) 0.94 (0.63-1.4) 7.76E-01 13.50 (7.44-19.56) 1.24E-05 
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Figure 3.1. Estimated ORs for COPD stratified by deciles of a lung function PRS and by 
ever-smoking 
 




Note: Estimated ORs for COPD comparing ever-smokers to never-smokers were calculated for 








Note: Estimated ORs for COPD comparing the 2nd to 10th deciles of a lung function PRS to the 
1st decile (lowest) for a lung function PRS among never- and ever- smokers.
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Figure 3.3. Joint effects of pack-years and a lung function PRS on COPD risk  
 
 
Note: The y axis is log(OR) for COPD comparing each group to a reference group of low exposure to smoking (i.e. pack-
years≤10) in the lowest PRS group. This lowest PRS group represents the 1st decile of PRS (i.e. individual with a low genetic 
risk), while the highest PRS group represents 10th decile of PRS (individuals with a high genetic risk).
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Supplemental Table 3.1. Overall associations of smoking (Never/Former/Current and 
Pack-years with never smoker as reference) with COPD 
Exposure OR (95% CI) 
Smoking status 
Never smoker 1.00 (Reference) 
Former smoker 1.78 (1.72-1.84) 
Current smoker 5.47 (5.22-5.72) 
Category of Pack-Years 
Never smoker 1.00 (Reference) 
≤10 1.41 (1.33-1.51) 
10.1-20 2.01 (1.91-2.12) 
20.1-30 1.82 (1.72-1.92) 
30.1-40 3.34 (3.16-3.54) 
40.1-50 4.76 (4.44-5.11) 
>50 6.57 (6.13-7.04) 
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Supplemental Table 3. 2. Interaction between pack-years and PRS on the risk of COPD in ever-smokers 
 
Joint effects 
 Lowest PRS group Highest PRS group 
Pack-years n % of COPD case OR (95% CI) n % of COPD case OR (95% CI) 
≤10 1933 0.04 1.00 (Reference) 1769 0.13 4.05 (3.07-5.33) 
10.1-20 1886 0.05 1.24 (0.9-1.7) 1927 0.2 5.73 (4.40-7.46) 
20.1-30 1312 0.08 1.38 (1.00-1.89) 1281 0.31 6.79 (5.16-8.94) 
30.1-40 751 0.17 2.75 (2-3.77) 896 0.47 12 (9.05-15.92) 
40.1-50 408 0.27 4.9 (3.5-6.85) 472 0.56 16.86 (12.35-23.01) 
>50 458 0.32 5.79 (4.19-8.00) 471 0.65 22.11 (16.10-30.36) 
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Supplemental Table 3.3. Interaction between smoking (Never/Former/Current and Pack-years with never smoker as 
reference) and PRS on the risk of COPD 
 Stratum-specific effects Joint effects 
 
Lowest PRS group Highest PRS group 
Interaction on multiplicative 
scale 








% of COPD 
case 
OR (95% CI) n 
% of COPD 
case 
OR (95% CI) OR (95% CI) P 
RERI (95% 
CI) 
P OR (95% CI) OR (95% CI) 
Smoking status             
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>50 458 0.32 
8.43 (6.62-
10.74) 











Supplemental Figure 3.1. Joint effects of smoking measures and a lung function PRS on 
COPD risk  
 
 
Supplemental Figure 3.1a. Smoking status 
 
 
Supplemental Figure 3.1b. Pack-years 
 
Note: The y axis is log(OR) for COPD comparing each group to a reference group of never-
smoker with the lowest PRS (low genetic risk, i.e. the 1st decile of PRS). The highest PRS 
group represents 10th decile of PRS (high genetic risk).
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Chapter 5. Summary of key findings and conclusions
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Chapter 5. Summary of key findings and conclusion 
 
Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death worldwide. 
Although cigarette smoking is the most important environmental risk factor, risk of COPD is 
influenced by the interplay between genetic and environmental risk factors. COPD is highly 
heterogenous with two main subtypes, emphysema and small airway disease, which can be 
quantitatively measured by computed tomography (CT) imaging. Most previous research has 
relied on identifying associations of common variants with quantitative measures of emphysema 
in cross-sectional studies. The adverse effects of smoking on risk of COPD vary by an 
individual’s susceptibility, raising the possibility of gene-by-smoking interaction. However, little is 
known about gene-by-smoking interactions on COPD risk to date. This dissertation addresses 
these issues with the following specific aims:  
 
Aim 1. To examine genetic variants for association with change in quantitative emphysema 
measured by CT imaging from two longitudinal cohort studies: COPDGene and Evaluation 
of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). 
 
Aim 2. To identify novel genetic variants for risk of COPD while accounting for potential 
smoking interactions and assess the gene-by-smoking interactions on risk of COPD at 
known COPD and lung function GWAS loci. 
 
Aim 3. To examine whether effects of smoking on COPD risk are modified by a polygenic 




Summary of key findings 
 
Analysis of longitudinal change in quantitative emphysema. We conducted a GWAS to identify 
variants associated with annual change in quantitative emphysema measured by CT scans and 
examined effects of variants previously associated with cross-sectional quantitative 
emphysema, COPD and spirometric measures of lung function on the annual change in 
emphysema from two large cohorts, COPDGene and ECLIPSE. None of single nucleotide 
polymorphisms (SNPs) yielded genome-wide significance. However, in our candidate region 
analysis, we identified significant associations for a variant in DSP and a polygenic risk score 
(PRS) based on spirometric measures of lung function with the annual change in emphysema in 
individuals of European ancestry. This study was published on the “Respiratory Research” 
journal in 2019 1.  
 
Analysis of SNP-by-smoking interaction on COPD. We conducted a genome-wide gene-by-
smoking interaction study of risk to COPD, using a 2df joint test for genetic main effects and 
gene-by-smoking interaction effects on COPD risk. Most of the significant signals from the 2df 
test had been reported in previous GWAS of COPD. However, we identified two loci, 16q22.1 – 
SMPD3 and 19q13.2 – EGLN2, reaching genome-wide significance. We detected a genome-
wide significant interaction with smoking at the 15q25.1 region which contains – CHRNB4, 
previously identified in studies of COPD and smoking behavior. We confirmed SERPINA1 PI*Z-
by-smoking interaction on risk to COPD.  
 
Analysis of polygenic risk score-by-smoking interaction on risk to COPD. We focused on tests of 
gene-by-smoking interaction on COPD risk using a risk score based on 279 genetic risk factors 
for lung function identified from a previous GWAS of lung function in the UK Biobank study. Our 
study provides evidence for interaction between smoking and PRS on the risk of COPD. The 
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results were most compelling under an additive model. Particularly, among ever-smokers, our 
analyses showed strong evidence for a super-additive interaction between smoking dose and 
PRS on the risk of COPD.  
 
Strengths and limitations 
 
Strengths. This dissertation has several key strengths. First, the COPDGene and ECLIPSE 
studies are the largest cohorts to date to measure emphysema using chest CT scans. CT 
measures were carefully quantified, allowing to assess the progression of emphysema and its 
genetic factors. Second, this dissertation included large sample size over 200,000 subjects from 
the UK Biobank (UKB), a large-scale cohort recruiting volunteers throughout UK, collecting a 
wide range of phenotypes as well as genetic data. Third, this is the first GWAS investigating 
change in quantitative emphysema measured by CT imaging in longitudinal data. This provides 
the first evidence of associations of a DSP variant and a lung function PRS with longitudinal 
emphysema progression measured by CT scan. Fourth, this is one of the first studies to 
investigate gene-by-smoking interaction at the genome-wide scale on risk to COPD itself. Fifth, 
this study provides evidence of additive interaction between smoking and a lung function PRS 
on the risk of COPD for the first time.  
 
Limitations. This dissertation should be interpreted under several limitations. First, the follow-up 
period in our study of quantitative measures of emphysema may be too short to capture the 
natural history of emphysema in adults. Second, we only included independent subjects of 
European ancestry to test for interactions using the UK Biobank data. Third, the additive 
interaction measures can be exaggerated in analysis of PRS-by-smoking interaction on risk to 
COPD. We assessed the additive interaction using Relative Excess Risk due to Interaction 
(RERI) measure assuming the disease was rare in our population, but the high prevalence of 
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COPD (>10%) in the sub-groups for the stratified analysis of PRS and smoking groups may 
undermine this assumption. Fourth, we did not calculate the actual absolute risk and evaluate 
the risk differences when estimating the additive interaction between smoking and a lung 
function PRS. Fifth, a “healthy volunteer” selection bias exists in the UKB study. The UKB 
cohort is not representative of the general population; UKB participants are less likely to smoke 
and have fewer self-reported health conditions compared with the general population of the UK 
2. However, generalizability is not necessary to make an inference of associations. Its large 




Additional investigation of the DSP gene. We identified an association between rs2076295 in 
the DSP gene and longitudinal change in quantitative emphysema. This variant is also 
associated with increased risk of COPD 3, reduced lung function 4, as well as decreased risk of 
pulmonary fibrosis 5. Whether this association represents true progression of emphysema or (for 
the opposite allele) development of fibrosis, or both needs confirmation in further studies. 
 
Ongoing longitudinal follow-up. Our follow-up period (approximately 5.5 years in COPDGene 
and 2.6 years in ECLIPSE) is sufficient to show emphysema progression, but very short in the 
context of the natural history of emphysema. Longer follow-up may provide more accurate data 
to estimate the emphysema progression. 
 
Diversity of population. Investigation of more ethnically diverse populations should lead to more 
robust inferences about gene-by-environment interactions by increasing diversity of not only 




Integration with “-omics” data. Integration of genetic markers and other “-omics” data 
(transcriptomic, proteomic or epigenomic data) would be helpful to understand gene-by-smoking 
interactions on COPD risk or more broadly, gene-by-environment interactions. For example, 
genetic markers influencing other biomarkers such as expression Quantitative Trait Loci (eQTL) 
may be more likely to interact with smoking 7. 
 
Evaluation of additive interaction. Additive interactions are less explored than multiplicative 
interactions in gene-by-environment interaction studies, although it has more public health 
relevance. Our finding highlights the importance of assessing the additive interaction as well as 
the multiplicative interaction in future gene-by-environment interaction studies.   
 
Public health significances 
 
This dissertation has public health significances. Particularly, the evidence of super-additive 
interaction between smoking and PRS indicates reduction in risk of COPD by smoking 
cessation programs should be larger among individuals at higher genetic risk of COPD. Our 
findings provide proof-of-principle for the potential application of genetic information in targeting 
smoking intervention programs. However, ethical issues to use genetic information in public 
health settings should be carefully considered. Improved understanding of the genetics and 
potential gene-by-environment interactions influencing risk to COPD may aid in the discovery of 
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